Note: Descriptions are shown in the official language in which they were submitted.
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
ANTI-TIM-3 ANTIBODIES AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No.
62/538,277,
.. filed on July 28, 2017. The disclosure of which is incorporated herein by
reference in its
entirety.
FIELD OF THE INVENTION
[0002] This invention relates to monoclonal anti-TIM-3 antibodies, nucleic
acids and
expression vectors encoding the antibodies, recombinant cells containing the
vectors, and
compositions comprising the antibodies. Methods of making the antibodies, and
methods
of using the antibodies to treat diseases including cancer, inflammatory
diseases,
autoimmune diseases, infectious diseases, metabolic diseases (e.g., obesity,
insulin
resistance, and diabetes), and/or associated complications are also provided.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0003] This application contains a sequence listing, which is submitted
electronically via
EFS-Web as an ASCII formatted sequence listing with a file name "689204.3W0
Sequence Listing" and a creation date of July 25, 2018, and having a size of
78 kb. The
sequence listing submitted via EFS-Web is part of the specification and is
herein
incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
[0004] T-cell immunoglobulin and mucin-domain containing molecule 3 (TIM-3) is
a
receptor expressed on myeloid cells, including dendritic cells (DCs),
macrophages and
NK cells, and a subset of lymphoid cells, such as T cells. The documented
ligands for
TIM-3 include galectin-9 (Gal-9), phosphatidylserine (PtdSer), and high
mobility group
protein B1 (HMGB1). The ligations of Gal-9 and PtdSer are mediated by the
variable
immunoglobulin domain (IgV) of TIM-3. The glycosylation of IgV is required for
Gal-9
binding but not for PtdSer binding. By interacting with these ligands, TIM-3
modulates
both innate and adaptive immunities. HMGB1 also plays an important role in
chronic
1
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
inflammation of the adipose tissue in obesity, suggesting that TIM-3 function
could be
involved in inflammation-related metabolic changes.
[0005] On the surface of myeloid cells, high expression of TIM-3 inhibits the
production of cytokines from macrophages and DCs. The inhibition can be
reversed by
stimulus from T cells and similarly by blocking monoclonal antibodies. In
tumors, the
cancer protective and promoting M2 macrophages are associated with high level
of TIM-
3 expression, whereas the cancer fighting M1 macrophages are associated with
low level
of TIM-3 expression. It remains to be demonstrated whether blocking TIM-3 by a
monoclonal antibody can convert M2 to cancer engulfing M1 macrophages.
[0006] On the surface of T cells, TIM-3 modulates adaptive immunity by
interacting
with the ligand Gal-9. TIM-3 is expressed on CD4+ helper (Thl and Th17),
regulatory
(Treg) and CD8+ cytotoxic 1 (Tc1) T cells. Chronic ligation of TIM-3 to Gal-9
induces
apoptosis of Thl cells, downregulating immune response and duration. The
surface
expression, or possibly the function, of TIM-3 depends on the binding to
CEACAM1 in
both cis and trans. Remarkably, TIM-3 is usually found on CD8+ T cells
expressing
immune-repressing PD-1. It has been proposed that TIM-3 and PD-1 are co-
suppressors
leading to dysfunctional intratumoral T cells. This makes a TIM-3 antagonist
antibody a
potentially great therapeutic alone and in combination with a PD-1/PDL-1
and/or other
immuno-oncology therapy.
[0007] In addition to modulating immune cells, TIM-3 is also highly expressed
on the
leukemic stem cells (LSCs) in acute myeloid leukemia (AML). On LSCs, TIM-3 and
Gal-9 form an autocrine stimulatory loop to drive self-renewal pathways of
cancerous
LSCs and leukemic progression. Interestingly, TIM-3 is not present on the
surface of
hematopoietic stem cells (HSCs), providing an opportunity to treat AML and
other
myeloid leukemia disorders using a blocking/depleting/cytotoxic therapeutic
TIM-3
antibody.
[0008] TIM-3 modulates the activities of both innate and adaptive immune
cells. A
TIM-3 blocking monoclonal antibody has the potential to unleash the immune
system via
unique mechanisms to eliminate cancer cells.
2
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
BRIEF SUMMARY OF THE INVENTION
[0009] In one general aspect, the invention relates to isolated monoclonal
antibodies or
antigen-binding fragments thereof that bind TIM-3.
[0010] Provided are isolated monoclonal antibodies or antigen-binding
fragments
thereof comprising a heavy chain complementarity determining region 1 (HCDRI),
HCDR2, HCDR3, a light chain complementarity determining region 1 (LCDRI),
LCDR2,
and LCDR3, having the polypeptide sequences of:
(1) SEQ ID NOs:43, 44, 169, 106, 107, and 170, respectively;
(2) SEQ ID NOs:55, 56, 57, 118, 119, and 120, respectively;
(3) SEQ ID NOs:58, 59, 60, 121, 122, and 123, respectively;
(4) SEQ ID NOs:61, 62, 63, 124, 125, and 126, respectively;
(5) SEQ ID NOs:64, 65, 66, 127, 128, and 129, respectively;
(6) SEQ ID NOs:67, 68, 69, 130, 131, and 132, respectively;
(7) SEQ ID NOs:70, 71, 72, 133, 134, and 135, respectively;
(8) SEQ ID NOs:73, 74, 75, 136, 137, and 138, respectively;
(9) SEQ ID NOs:76, 77, 78, 139, 140, and 141, respectively;
(10) SEQ ID NOs:79, 80, 81, 142, 143, and 144, respectively;
(11) SEQ ID NOs:82, 83, 84, 145, 146, and 147, respectively;
(12) SEQ ID NOs:85, 86, 87, 148, 149, and 150, respectively;
(13) SEQ ID NOs:88, 89, 90, 151, 152, and 153, respectively;
(14) SEQ ID NOs:91, 92, 93, 154, 155, and 156, respectively;
(15) SEQ ID NOs:94, 95, 96, 157, 158, and 159, respectively;
(16) SEQ ID NOs:97, 98, 99, 160, 161, and 162, respectively;
(17) SEQ ID NOs:100, 101, 102, 163, 164, and 165, respectively; or
(18) SEQ ID NOs:103, 104, 105, 166, 167, and 168, respectively;
wherein the antibody or antigen-binding fragment thereof specifically binds
TIM-3,
preferably human TIM-3. SEQ ID NO:169 is represented by the amino acid
sequence
ARDX1X2DY, wherein Xi is an amino acid selected from the group consisting of
A, T,
and L, and wherein X2 is an amino acid selected from M and E. SEQ ID NO:170 is
represented by the amino acid sequence SQX1X2HVPX3T, wherein Xi is an amino
acid
3
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
selected from the group consisting of N, T, and S, X2 is an amino acid
selected from T
and I, and X3 is an amino acid selected from W and Y.
[0011] In certain embodiments, the isolated monoclonal antibody or antigen-
binding
fragment comprise a heavy chain variable region having a polypeptide sequence
at least
95% identical to SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27,
29, 31, 33, 35,
37, 39, or 41 or a light chain variable region having a polypeptide sequence
at least 95%
identical to SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30,
32, 34, 36, 38,
40, or 42.
[0012] In certain embodiments, the isolated monoclonal antibody or antigen-
binding
fragment comprise:
(a) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:1, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:2;
(b) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:3, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:4;
(c) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:5, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:6;
(d) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:7, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:8;
(e) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:9, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:10;
(f) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:11, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:12;
(g) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:13, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:14;
4
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
(h) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:15, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:16;
(i) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:17, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:18;
(j) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:19, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:20;
(k) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:21, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:22;
(1) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:23, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:24;
(m) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:25, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:26;
(n) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:27, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:28;
(o) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:29, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:30;
(p) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:31, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:32;
(q) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:33, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:34;
5
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
(r) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:35, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:36;
(s) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:37, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:38;
(t) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:39, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:40; or
(u) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:41, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:42.
[0013] In certain embodiments, the isolated monoclonal antibody or antigen-
binding
fragment thereof is chimeric.
[0014] In certain embodiments, the isolated monoclonal antibody or antigen-
binding
fragment thereof is human or humanized.
[0015] In certain embodiments, the humanized monoclonal antibody or antigen-
binding
fragment thereof comprises:
(a) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:171, and a light chain variable region having the polypeptide sequence of
SEQ ID NO:175;
(b) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:172, and a light chain variable region having the polypeptide sequence of
SEQ ID NO:175;
(c) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:173, and a light chain variable region having the polypeptide sequence of
SEQ ID NO:176; or
(d) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:174, and a light chain variable region having the polypeptide sequence of
SEQ ID NO:176.
6
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[0016] In certain embodiments, the isolated monoclonal antibody or antigen-
binding
fragment thereof is capable of blocking binding of TIM-3 to phosphatidylserine
(PtdSer),
TIM-3 to galectin-9 (Gal-9), TIM-3 to carcinoembryonic antigen cell adhesion
molecule
1 (CEACAM1), and/or TIM-3 to high mobility group protein B1 (HMGB1).
[0017] Also provided are isolated nucleic acids encoding the monoclonal
antibodies or
antigen-binding fragments thereof of the invention disclosed herein.
[0018] Also provided are vectors comprising the isolated nucleic acids
encoding the
monoclonal antibodies or antigen-binding fragments thereof of the invention
[0019] Also provided are host cells comprising the vectors comprising the
isolated
nucleic acids encoding the monoclonal antibodies or antigen-binding fragments
thereof of
the invention.
[0020] In certain embodiments, provided is a pharmaceutical composition
comprising
an isolated monoclonal antibody or antigen-binding fragment thereof of the
invention and
a pharmaceutically acceptable carrier.
[0021] Also provided are methods of blocking binding of TIM-3 to
phosphatidylserine
(PtdSer), TIM-3 to galectin-9 (Gal-9), TIM-3 to carcinoembryonic antigen cell
adhesion
molecule 1 (CEACAM1), and/or TIM-3 to high mobility group protein B1 (HMGB1)
in a
subject in need thereof, comprising administering to the subject the
pharmaceutical
compositions of the invention.
[0022] Also provided are methods of treating cancer in a subject in need
thereof,
comprising administering to the subject the pharmaceutical compositions of the
invention.
The cancer can be any liquid or solid cancer, for example, it can be selected
from, but not
limited to, a lung cancer, a gastric cancer, a colon cancer, a hepatocellular
carcinoma, a
renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a
breast
cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a
pancreatic cancer,
a glioma, a glioblastoma, and other solid tumors, and a non-Hodgkin's lymphoma
(NHL),
an acute lymphocytic leukemia (ALL), a chronic lymphocytic leukemia (CLL), a
chronic
myelogenous leukemia (CML), a multiple myeloma (MM), an acute myeloid leukemia
(AML), and other liquid tumors.
7
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[0023] Also provided are methods of treating an infectious disease in a
subject in need
thereof, comprising administering to the subject the pharmaceutical
composition of the
invention.
[0024] Also provided are methods of treating an inflammatory disease in a
subject in
need thereof, comprising administering to the subject the pharmaceutical
compositions of
the invention.
[0025] Also provided are methods of treating an autoimmune disease in a
subject in
need thereof, comprising administering to the subject the pharmaceutical
compositions of
the invention.
[0026] Also provided are methods of treating a metabolic disease in a subject
in need
thereof, comprising administering to the subject the pharmaceutical
compositions of the
invention.
[0027] Also provided are methods of producing the monoclonal antibody or
antigen-
binding fragment thereof of the invention, comprising culturing a cell
comprising a
nucleic acid encoding the monoclonal antibody or antigen-binding fragment
under
conditions to produce the monoclonal antibody or antigen-binding fragment, and
recovering the antibody or antigen-binding fragment from the cell or culture.
[0028] Also provided are methods of producing a pharmaceutical composition
comprising the monoclonal antibody or antigen-binding fragment thereof of the
invention,
comprising combining the monoclonal antibody or antigen-binding fragment with
a
pharmaceutically acceptable carrier to obtain the pharmaceutical composition.
[0029] Also provided are methods of determining a level of TIM-3 in a subject.
The
methods comprise (a) obtaining a sample from the subject; (b) contacting the
sample with
an antibody or antigen-binding fragment thereof of the invention, and (c)
determining the
level of TIM-3 in the subject. In certain embodiments, the sample is a tissue
or blood
sample. The tissue sample can, for example, be a cancer tissue sample. The
blood sample
can, for example, comprise cancer cells.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The foregoing summary, as well as the following detailed description of
preferred embodiments of the present application, will be better understood
when read in
8
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
conjunction with the appended drawings. It should be understood, however, that
the
application is not limited to the precise embodiments shown in the drawings.
[0031] FIG. 1 shows the inhibition of human TIM-3 binding to PtdSer by anti-
TIM-3
monoclonal antibodies (mAbs). ELISA plates were coated with PtdSer or PtdChol,
washed and incubated with a pre-equilibrated mixture of purified antibodies at
various
concentrations and TIM3(ECD)-huFc. The plates were washed and then the signal
was
detected by incubation with HRP-coupled anti-huFc secondary antibody and then
a HRP
substrate. TIM-3 binding to PtdSer was used as 100% signal and TIM-3 binding
to
PtdChol as zero (background) to calculate percent of inhibition by a given
mAb. FIG. 1A
shows a graph of the inhibition of human TIM-3 binding to PtdSer by anti-TIM-3
antibodies 20-L10-A, 16-K5-A, 15-L23-A, and 2-K2-A. FIG. 1B shows a graph of
the
inhibition of human TIM-3 binding to PtdSer by anti-TIM-3 antibodies 12-G18-A,
5-
Cu-A, and 19-A14-A. FIG. 1C shows a graph of the inhibition of human TIM-3
binding
to PtdSer by anti-TIM-3 antibodies 10-M21-A, 18-N1-A, and 16-L3-A. FIG. 1D
shows a
graph of the inhibition of human TIM-3 binding to PtdSer by anti-TIM-3
antibodies 12-
M11-A, 5-K4-A, and 1645-A. FIG. 1E shows a graph of the inhibition of human
TIM-3
binding to PtdSer by anti-TIM-3 antibodies 7-P15-A, 8-F3-A, 10-015-A, and 18-
022-A.
FIG. 1F shows a graph of the inhibition of human TIM-3 binding to PtdSer by
anti-TIM-
3 antibodies 6-I13-A, 6-H6-A, and 7-N2-A.
[0032] FIG. 2 shows FACS binding analysis of anti-TIM-3 mAbs. The binding of
purified anti-TIM-3 mAbs to HEK293 cells transiently transfected with human
TIM-3
(labeled as "HuTIM-3 cells") or parental HEK293 cells (labeled as "CTL cells")
was
tested by FACS at 3 different concentrations. An anti-mouse secondary Ab
AlexaFluor488 was used for detection.
[0033] FIGS. 3A and 3B show the result of binding of chimeric and humanized
versions
of mAb 16-K5-A to recombinant human TIM-3(ECD)-6His immobilized on a plate in
an
ELISA assay.
DETAILED DESCRIPTION OF THE INVENTION
[0034] Various publications, articles and patents are cited or described in
the
background and throughout the specification; each of these references is
herein
9
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
incorporated by reference in its entirety. Discussion of documents, acts,
materials,
devices, articles or the like which has been included in the present
specification is for the
purpose of providing context for the invention. Such discussion is not an
admission that
any or all of these matters form part of the prior art with respect to any
inventions
disclosed or claimed.
[0035] Unless defined otherwise, all technical and scientific terms used
herein have the
same meaning as commonly understood to one of ordinary skill in the art to
which this
invention pertains. Otherwise, certain terms used herein have the meanings as
set forth in
the specification.
[0036] It must be noted that as used herein and in the appended claims, the
singular
forms "a," "an," and "the" include plural reference unless the context clearly
dictates
otherwise.
[0037] Unless otherwise stated, any numerical values, such as a concentration
or a
concentration range described herein, are to be understood as being modified
in all
instances by the term "about." Thus, a numerical value typically includes +
10% of the
recited value. For example, a concentration of 1 mg/mL includes 0.9 mg/mL to
1.1
mg/mL. Likewise, a concentration range of 1% to 10% (w/v) includes 0.9% (w/v)
to 11%
(w/v). As used herein, the use of a numerical range expressly includes all
possible
subranges, all individual numerical values within that range, including
integers within
.. such ranges and fractions of the values unless the context clearly
indicates otherwise.
[0038] Unless otherwise indicated, the term "at least" preceding a series of
elements is
to be understood to refer to every element in the series. Those skilled in the
art will
recognize, or be able to ascertain using no more than routine experimentation,
many
equivalents to the specific embodiments of the invention described herein.
Such
equivalents are intended to be encompassed by the invention.
[0039] As used herein, the terms "comprises," "comprising," "includes,"
"including,"
"has," "having," "contains" or "containing," or any other variation thereof,
will be
understood to imply the inclusion of a stated integer or group of integers but
not the
exclusion of any other integer or group of integers and are intended to be non-
exclusive
or open-ended. For example, a composition, a mixture, a process, a method, an
article, or
an apparatus that comprises a list of elements is not necessarily limited to
only those
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
elements but can include other elements not expressly listed or inherent to
such
composition, mixture, process, method, article, or apparatus. Further, unless
expressly
stated to the contrary, "or" refers to an inclusive or and not to an exclusive
or. For
example, a condition A or B is satisfied by any one of the following: A is
true (or present)
and B is false (or not present), A is false (or not present) and B is true (or
present), and
both A and B are true (or present).
[0040] As used herein, the conjunctive term "and/or" between multiple recited
elements is understood as encompassing both individual and combined options.
For
instance, where two elements are conjoined by "and/or," a first option refers
to the
applicability of the first element without the second. A second option refers
to the
applicability of the second element without the first. A third option refers
to the
applicability of the first and second elements together. Any one of these
options is
understood to fall within the meaning, and therefore satisfy the requirement
of the term
"and/or" as used herein. Concurrent applicability of more than one of the
options is also
understood to fall within the meaning, and therefore satisfy the requirement
of the term
"and/or."
[0041] As used herein, the term "consists of," or variations such as "consist
of' or
"consisting of," as used throughout the specification and claims, indicate the
inclusion of
any recited integer or group of integers, but that no additional integer or
group of integers
can be added to the specified method, structure, or composition.
[0042] As used herein, the term "consists essentially of" or variations such
as "consist
essentially of' or "consisting essentially of," as used throughout the
specification and
claims, indicate the inclusion of any recited integer or group of integers,
and the optional
inclusion of any recited integer or group of integers that do not materially
change the
basic or novel properties of the specified method, structure or composition.
See M.P.E.P.
2111.03.
[0043] As used herein, "subject" means any animal, preferably a mammal, most
preferably a human. The term "mammal" as used herein, encompasses any mammal.
Examples of mammals include, but are not limited to, cows, horses, sheep,
pigs, cats,
dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., more preferably
a human.
11
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[0044] The words "right," "left," "lower," and "upper" designate directions in
the
drawings to which reference is made.
[0045] It should also be understood that the terms "about," "approximately,"
"generally," "substantially" and like terms, used herein when referring to a
dimension or
characteristic of a component of the preferred invention, indicate that the
described
dimension/characteristic is not a strict boundary or parameter and does not
exclude minor
variations therefrom that are functionally the same or similar, as would be
understood by
one having ordinary skill in the art. At a minimum, such references that
include a
numerical parameter would include variations that, using mathematical and
industrial
principles accepted in the art (e.g., rounding, measurement or other
systematic errors,
manufacturing tolerances, etc.), would not vary the least significant digit.
[0046] The terms "identical" or percent "identity," in the context of two or
more
nucleic acids or polypeptide sequences (e.g., anti-TIM-3 antibodies, TIM-3
polypeptides,
and polynucleotides that encode them), refer to two or more sequences or
subsequences
that are the same or have a specified percentage of amino acid residues or
nucleotides
that are the same, when compared and aligned for maximum correspondence, as
measured using one of the following sequence comparison algorithms or by
visual
inspection.
[0047] For sequence comparison, typically one sequence acts as a reference
sequence,
to which test sequences are compared. When using a sequence comparison
algorithm,
test and reference sequences are input into a computer, subsequence
coordinates are
designated, if necessary, and sequence algorithm program parameters are
designated.
The sequence comparison algorithm then calculates the percent sequence
identity for the
test sequence(s) relative to the reference sequence, based on the designated
program
parameters.
[0048] Optimal alignment of sequences for comparison can be conducted, e.g.,
by the
local homology algorithm of Smith & Waterman, Adv. Appl Math. 2:482 (1981), by
the
homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443
(1970), by
the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci.
USA
85:2444 (1988), by computerized implementations of these algorithms (GAP,
BESTFIT,
FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics
Computer
12
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally,
Current
Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols,
a joint
venture between Greene Publishing Associates, Inc. and John Wiley & Sons,
Inc., (1995
Supplement) (Ausubel)).
[0049] Examples of algorithms that are suitable for determining percent
sequence
identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which
are
described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et
al. (1997)
Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST
analyses is publicly available through the National Center for Biotechnology
Information.
This algorithm involves first identifying high scoring sequence pairs (HSPs)
by
identifying short words of length W in the query sequence, which either match
or satisfy
some positive-valued threshold score T when aligned with a word of the same
length in a
database sequence. T is referred to as the neighborhood word score threshold
(Altschul
et al, supra). These initial neighborhood word hits act as seeds for
initiating searches to
find longer HSPs containing them. The word hits are then extended in both
directions
along each sequence for as far as the cumulative alignment score can be
increased.
[0050] Cumulative scores are calculated using, for nucleotide sequences, the
parameters M (reward score for a pair of matching residues; always > 0) and N
(penalty
score for mismatching residues; always < 0). For amino acid sequences, a
scoring matrix
is used to calculate the cumulative score. Extension of the word hits in each
direction are
halted when: the cumulative alignment score falls off by the quantity X from
its
maximum achieved value; the cumulative score goes to zero or below, due to the
accumulation of one or more negative-scoring residue alignments; or the end of
either
sequence is reached. The BLAST algorithm parameters W, T, and X determine the
sensitivity and speed of the alignment. The BLASTN program (for nucleotide
sequences)
uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4,
and a
comparison of both strands. For amino acid sequences, the BLASTP program uses
as
defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62
scoring
matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).
[0051] In addition to calculating percent sequence identity, the BLAST
algorithm also
performs a statistical analysis of the similarity between two sequences (see,
e.g., Karlin &
13
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of
similarity
provided by the BLAST algorithm is the smallest sum probability (P(N)), which
provides
an indication of the probability by which a match between two nucleotide or
amino acid
sequences would occur by chance. For example, a nucleic acid is considered
similar to a
reference sequence if the smallest sum probability in a comparison of the test
nucleic acid
to the reference nucleic acid is less than about 0.1, more preferably less
than about 0.01,
and most preferably less than about 0.001.
[0052] A further indication that two nucleic acid sequences or polypeptides
are
substantially identical is that the polypeptide encoded by the first nucleic
acid is
immunologically cross reactive with the polypeptide encoded by the second
nucleic acid,
as described below. Thus, a polypeptide is typically substantially identical
to a second
polypeptide, for example, where the two peptides differ only by conservative
substitutions. Another indication that two nucleic acid sequences are
substantially
identical is that the two molecules hybridize to each other under stringent
conditions.
[0053] Antibodies
[0054] The invention generally relates to isolated anti-TIM-3 antibodies,
nucleic acids
and expression vectors encoding the antibodies, recombinant cells containing
the vectors,
and compositions comprising the antibodies. Methods of making the antibodies,
and
methods of using the antibodies to treat diseases including cancer,
inflammatory diseases,
autoimmune diseases, metabolic diseases, and/or infectious diseases are also
provided.
The antibodies of the invention possess one or more desirable functional
properties,
including but not limited to high-affinity binding to TIM-3, high specificity
to TIM-3, the
ability to block the binding of TIM-3 to phosphatidylserine (PtdSer), the
ability to block
the binding of TIM-3 to galectin-9, the ability to block the binding of TIM-3
to
.. carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), the ability to
block the
binding of TIM-3 to high mobility group protein B1 (HMGB1), the ability to
stimulate
the production of cytokines such as, but not limited to, IL-2 and IFN-y, and
the ability to
inhibit tumor growth in animal models and subjects when administered alone or
in
combination with other anti-cancer therapies
[0055] In a general aspect, the invention relates to isolated monoclonal
antibodies or
antigen-binding fragments thereof that bind TIM-3.
14
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[0056] As used herein, the term "antibody" is used in a broad sense and
includes
immunoglobulin or antibody molecules including human, humanized, composite and
chimeric antibodies and antibody fragments that are monoclonal or polyclonal.
In general,
antibodies are proteins or peptide chains that exhibit binding specificity to
a specific
.. antigen. Antibody structures are well known. Immunoglobulins can be
assigned to five
major classes (i.e., IgA, IgD, IgE, IgG and IgM), depending on the heavy chain
constant
domain amino acid sequence. IgA and IgG are further sub-classified as the
isotypes IgAl,
IgA2, IgGl, IgG2, IgG3 and IgG4. Accordingly, the antibodies of the invention
can be of
any of the five major classes or corresponding sub-classes. Preferably, the
antibodies of
the invention are IgGl, IgG2, IgG3 or IgG4. Antibody light chains of
vertebrate species
can be assigned to one of two clearly distinct types, namely kappa and lambda,
based on
the amino acid sequences of their constant domains. Accordingly, the
antibodies of the
invention can contain a kappa or lambda light chain constant domain. According
to
particular embodiments, the antibodies of the invention include heavy and/or
light chain
constant regions from rat or human antibodies. In addition to the heavy and
light constant
domains, antibodies contain an antigen-binding region that is made up of a
light chain
variable region and a heavy chain variable region, each of which contains
three domains
(i.e., complementarity determining regions 1-3; CDR1, CDR2, and CDR3). The
light
chain variable region domains are alternatively referred to as LCDR1, LCDR2,
and
LCRD3, and the heavy chain variable region domains are alternatively referred
to as
HCDR1, HCRD2, and HCDR3.
[0057] As used herein, the term an "isolated antibody" refers to an antibody
which is
substantially free of other antibodies having different antigenic
specificities (e.g., an
isolated antibody that specifically binds to TIM-3 is substantially free of
antibodies that
do not bind to TIM-3). In addition, an isolated antibody is substantially free
of other
cellular material and/or chemicals.
[0058] As used herein, the term "monoclonal antibody" refers to an antibody
obtained
from a population of substantially homogeneous antibodies, i.e., the
individual antibodies
comprising the population are identical except for possible naturally
occurring mutations
.. that may be present in minor amounts The monoclonal antibodies of the
invention can be
made by the hybridoma method, phage display technology, single lymphocyte gene
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
cloning technology, or by recombinant DNA methods. For example, the monoclonal
antibodies can be produced by a hybridoma which includes a B cell obtained
from a
transgenic nonhuman animal, such as a transgenic mouse or rat, having a genome
comprising a human heavy chain transgene and a light chain transgene
[0059] As used herein, the term "antigen-binding fragment" refers to an
antibody
fragment such as, for example, a diabody, a Fab, a Fab', a F(ab')2, an Fv
fragment, a
disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFy (dsFv-
dsFv'), a
disulfide stabilized diabody (ds diabody), a single-chain antibody molecule
(scFv), a
single domain antibody (sdab) an scFv dimer (bivalent diabody), a
multispecific antibody
formed from a portion of an antibody comprising one or more CDRs, a camelized
single
domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or
any
other antibody fragment that binds to an antigen but does not comprise a
complete
antibody structure. An antigen-binding fragment is capable of binding to the
same
antigen to which the parent antibody or a parent antibody fragment binds.
According to
particular embodiments, the antigen-binding fragment comprises a light chain
variable
region, a light chain constant region, and an Fd segment of the heavy chain.
According to
other particular embodiments, the antigen-binding fragment comprises Fab and
F(ab').
[0060] As used herein, the term "single-chain antibody" refers to a
conventional single-
chain antibody in the field, which comprises a heavy chain variable region and
a light
chain variable region connected by a short peptide of about 15 to about 20
amino acids.
As used herein, the term "single domain antibody" refers to a conventional
single domain
antibody in the field, which comprises a heavy chain variable region and a
heavy chain
constant region or which comprises only a heavy chain variable region
[0061] As used herein, the term "human antibody" refers to an antibody
produced by a
human or an antibody having an amino acid sequence corresponding to an
antibody
produced by a human made using any technique known in the art. This definition
of a
human antibody includes intact or full-length antibodies, fragments thereof,
and/or
antibodies comprising at least one human heavy and/or light chain polypeptide.
[0062] As used herein, the term "humanized antibody" refers to a non-human
antibody
that is modified to increase the sequence homology to that of a human
antibody, such that
16
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
the antigen-binding properties of the antibody are retained, but its
antigenicity in the
human body is reduced.
[0063] As used herein, the term "chimeric antibody" refers to an antibody
wherein the
amino acid sequence of the immunoglobulin molecule is derived from two or more
.. species. The variable region of both the light and heavy chains often
corresponds to the
variable region of an antibody derived from one species of mammal (e.g.,
mouse, rat,
rabbit, etc.) having the desired specificity, affinity, and capability, while
the constant
regions correspond to the sequences of an antibody derived from another
species of
mammal (e.g., human) to avoid eliciting an immune response in that species.
[0064] As used herein, the term "multispecific antibody" refers to an antibody
that
comprises a plurality of immunoglobulin variable domain sequences, wherein a
first
immunoglobulin variable domain sequence of the plurality has binding
specificity for a
first epitope and a second immunoglobulin variable domain sequence of the
plurality has
binding specificity for a second epitope. In an embodiment, the first and
second epitopes
are on the same antigen, e.gõ the same protein (or subunit of a multimeric
protein). In an
embodiment, the first and second epitopes overlap or substantially overlap. In
an
embodiment, the first and second epitopes do not overlap or do not
substantially overlap.
In an embodiment, the first and second epitopes are on different antigens,
e.g., the
different proteins (or different subunits of a multimeric protein). In an
embodiment, a
multispecific antibody comprises a third, fourth, or fifth immunoglobulin
variable domain.
In an embodiment, a multispecific antibody is a bispecific antibody molecule,
a
trispecific antibody, or a tetraspecific antibody molecule.
[0065] As used herein, the term "bispecifc antibody" refers to a multispecific
antibody
that binds no more than two epitopes or two antigens. A bispecific antibody is
characterized by a first immunoglobulin variable domain sequence which has
binding
specificity for a first epitope and a second immunoglobulin variable domain
sequence
that has binding specificity for a second epitope. In an embodiment, the first
and second
epitopes are on the same antigen, e.g., the same protein (or subunit of a
multimeric
protein). In an embodiment, the first and second epitopes overlap or
substantially overlap.
In an embodiment the first and second epitopes are on different antigens,
e.g., the
different proteins (or different subunits of a multimeric protein). In an
embodiment a
17
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
bispecific antibody comprises a heavy chain variable domain sequence and a
light chain
variable domain sequence which have binding specificity for a first epitope
and a heavy
chain variable domain sequence and a light chain variable domain sequence
which have
binding specificity for a second epitope. In an embodiment, a bispecific
antibody
comprises a half antibody, or fragment thereof, having binding specificity for
a first
epitope and a half antibody, or fragment thereof, having binding specificity
for a second
epitope. In an embodiment, a bispecific antibody comprises a scFv, or fragment
thereof,
having binding specificity for a first epitope, and a scFv, or fragment
thereof, having
binding specificity for a second epitope. In an embodiment, the first epitope
is located on
TIM-3 and the second epitope is located on PD-1, PD-L1, LAG-3, CTLA-4, EGFR,
HER-2, CD19, CD20, CD33, DLL-3, CD73, apelin, CD3, CD47, TIP-1, CLDN18.2,
FOLR1 and/or other tumor associated immune suppressors or surface antigens.
[0066] As used herein, the term "TIM-3" refers to the T-cell immunoglobulin
and
mucin-domain containing molecule 3 protein, a receptor expressed on myeloid
cells,
.. including dendritic cells (DCs), macrophages and natural killer (NK) cells,
and a subset
of lymphoid cells, such as T cells. TIM-3 is capable of binding to
phosphatidylserine
(PtdSer), which is the principal signal for the phagocytosis of apoptotic
bodies or cells.
When the binding of PtdSer and TIM-3 is blocked with specific antibodies,
apoptotic
bodies are not removed, which can induce immunological abnormalities, such as
the
.. generation of autoantibodies (reviewed in Ocana-Guzman et al., "TIM-3
regulates
distinct functions in macrophages," Frontiers in Immunology Vol. 7, Art. 229
(2016)).
TIM-3 can regulate the production and release of cytokines in monocytes and
macrophages (reviewed in Ocana-Guzman et al., Id). The term "human TIM-3"
refers to
a TIM-3 originated from a human. An exemplary amino acid sequence of a human
TIM-3
is represented in GenBank Accession No. Q8TDQ0.3 or GenBank Accession No.
NP 116171.3 (SEQ ID NO:177).
[0067] As used herein, an antibody that "specifically binds to TIM-3" refers
to an
antibody that binds to a TIM-3, preferably a human TIM-3, with a KD of 1x 10-7
M or
less, preferably lx10 8M or less, more preferably 5x 10 9M or less, 1x10 9M or
less,
5 x10 1 M or less, or lx10 I M or less. The term "KD" refers to the
dissociation
constant, which is obtained from the ratio of Kd to Ka (i.e., Kd/Ka) and is
expressed as a
18
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
molar concentration (M). KD values for antibodies can be determined using
methods in
the art in view of the present disclosure. For example, the KD of an antibody
can be
determined by using surface plasmon resonance, such as by using a biosensor
system,
e.g., a Biacore system, or by using bio-layer interferometry technology, such
as an
Octet RED96 system.
[0068] The smaller the value of the KD of an antibody, the higher affinity
that the
antibody binds to a target antigen.
[0069] According to a particular aspect, the invention relates to an isolated
monoclonal
antibody or antigen-binding fragment thereof comprising a heavy chain
complementarity
determining region 1 (HCDR1), a HCDR2, a HCDR3, a light chain complementarity
determining region 1 (LCDR1), a LCDR2, and a LCDR3, having the polypeptide
sequences of:
(1) SEQ ID NOs:43, 44, 169, 106, 107, and 170, respectively;
(2) SEQ ID NOs:55, 56, 57, 118, 119, and 120, respectively;
(3) SEQ ID NOs:58, 59, 60, 121, 122, and 123, respectively;
(4) SEQ ID NOs:61, 62, 63, 124, 125, and 126, respectively;
(5) SEQ ID NOs:64, 65, 66, 127, 128, and 129, respectively;
(6) SEQ ID NOs:67, 68, 69, 130, 131, and 132, respectively;
(7) SEQ ID NOs:70, 71, 72, 133, 134, and 135, respectively;
(8) SEQ ID NOs:73, 74, 75, 136, 137, and 138, respectively;
(9) SEQ ID NOs:76, 77, 78, 139, 140, and 141, respectively;
(10) SEQ ID NOs:79, 80, 81, 142, 143, and 144, respectively;
(11) SEQ ID NOs:82, 83, 84, 145, 146, and 147, respectively;
(12) SEQ ID NOs:85, 86, 87, 148, 149, and 150, respectively;
(13) SEQ ID NOs:88, 89, 90, 151, 152, and 153, respectively;
(14) SEQ ID NOs:91, 92, 93, 154, 155, and 156, respectively;
(15) SEQ ID NOs:94, 95, 96, 157, 158, and 159, respectively;
(16) SEQ ID NOs:97, 98, 99, 160, 161, and 162, respectively;
(17) SEQ ID NOs:100, 101, 102, 163, 164, and 165, respectively; or
(18) SEQ ID NOs:103, 104, 105, 166, 167, and 168, respectively;
19
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
wherein the antibody or antigen-binding fragment thereof specifically binds
TIM-3,
preferably human TIM-3.
[0070] SEQ ID NO:169 is represented by the amino acid sequence ARDX1X2DY,
wherein X1 is an amino acid selected from the group consisting of A, T, and L,
and
wherein X2 is an amino acid selected from M and E.
[0071] SEQ ID NO:170 is represented by the amino acid sequence SQX1X2HVPX3T,
wherein X1 is an amino acid selected from the group consisting of N, T, and S,
X2 is an
amino acid selected from T and I, and X3 is an amino acid selected from W and
Y.
[0072] According to another particular aspect, the invention relates to an
isolated
monoclonal antibody or antigen-binding fragment thereof comprising a heavy
chain
variable region having a polypeptide sequence at least 85%, preferably 90%,
more
preferably 95% identical to one of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17,
19, 21, 23, 25,
27, 29, 31, 33, 35, 37, 39, or 41, or a light chain variable region having a
polypeptide
sequence at least 85%, preferably 90%, more preferably 95% identical to one of
SEQ ID
NOs:2, 4,6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40,
or 42.
According to one preferred embodiment, the isolated monoclonal antibody or
antigen-
binding fragment thereof of the invention comprises a heavy chain variable
region having
the polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35,
37, 39, or 41,
and a light chain variable region having a polypeptide sequence at least 85%,
preferably
90%, more preferably 95% identical to SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16,
18, 20, 22,
24, 26, 28, 30, 32, 34, 36, 38, 40, or 42, respectively.
[0073] According to another particular aspect, the invention relates to an
isolated
monoclonal antibody or antigen-binding fragment thereof of the invention,
comprising:
a. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:1, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:2;
b. a heavy chain variable region having the polypeptide sequence
of SEQ ID
NO:3, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:4;
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
c. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:5, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:6;
d. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:7, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:8;
e. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:9, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:10;
f. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:11, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:12;
g. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:13, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:14;
h. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:15, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:16;
i. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:17, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:18;
j. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:19, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:20;
k. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:21, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:22;
1. a heavy chain variable region having the polypeptide sequence
of SEQ ID
NO:23, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:24;
21
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
m. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:25, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:26;
n. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:27, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:28;
o. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:29, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:30;
p. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:31, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:32;
q. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:33, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:34;
r. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:35, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:36;
s. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:37, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:38;
t. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:39, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:40; or
u. a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:41, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:42.
[0074] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:43, 44, 45,
106,
107, and 108, respectively. In another embodiment, the isolated monoclonal
antibody or
22
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:1, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:2. Preferably,
the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:1; and a
light chain
variable region having the polypeptide sequence of SEQ ID NO:2.
[0075] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:46, 47, 48,
109,
110, and 111, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:3, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:4. Preferably,
the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:3; and a
light chain
variable region having the polypeptide sequence of SEQ ID NO:4.
[0076] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:49, 50, 51,
112,
113, and 114, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:5, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:6. Preferably,
the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:5; and a
light chain
variable region having the polypeptide sequence of SEQ ID NO:6.
[0077] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
23
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:52, 53, 54,
115,
116, and 117, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:7, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:8. Preferably,
the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:7; and a
light chain
variable region having the polypeptide sequence of SEQ ID NO:8.
[0078] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:55, 56, 57,
118,
119, and 120, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:9, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:10.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:9; and a
light chain
variable region having the polypeptide sequence of SEQ ID NO:10.
[0079] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:58, 59, 60,
121,
122, and 123, respectively. In another embodiment, the isolated monoclonal
antibody or
.. antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:11, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:12.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:11; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:12.
24
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[0080] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:61, 62, 63,
124,
125, and 126, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:13, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:14.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:13; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:14.
[0081] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:64, 65, 66,
127,
128, and 129, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:15, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:16.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:15; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:16.
[0082] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:67, 68, 69,
130,
131, and 132, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:17, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:18 Preferably,
the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
chain variable region having the polypeptide sequence of SEQ ID NO:17; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:18.
[0083] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:70, 71, 72,
133,
134, and 135, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:19, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:20.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:19; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:20.
[0084] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:73, 74, 75,
136,
137, and 138, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:21, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:22.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:21; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:22.
.. [0085] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:76, 77, 78,
139,
140, and 141, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:23, and a light chain variable region having a polypeptide sequence
at least
26
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:24.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:23; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:24.
[0086] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:79, 80, 81,
142,
143, and 144, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:25, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:26.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:25; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:26.
[0087] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:82, 83, 84,
145,
146, and 147, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:27, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:28.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:27; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:28.
[0088] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:85, 86, 87,
148,
149, and 150, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
27
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:29, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:30.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:29; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:30.
[0089] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:88, 89, 90,
151,
152, and 153, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:31, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:32.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:31; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:32.
[0090] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:91, 92, 93,
154,
155, and 156, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:33, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:34.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:33; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:34.
[0091] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:94, 95, 96,
157,
28
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
158, and 159, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:35, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:36.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:35; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:36.
[0092] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:97, 98, 99,
160,
161, and 162, respectively. In another embodiment, the isolated monoclonal
antibody or
antigen-binding fragment thereof comprises a heavy chain variable region
having a
polypeptide sequence at least 85%, preferably 90%, more preferably 95%
identical to
SEQ ID NO:37, and a light chain variable region having a polypeptide sequence
at least
85%, preferably 90%, more preferably 95% identical to SEQ ID NO:38.
Preferably, the
isolated monoclonal antibody or antigen-binding fragment thereof comprises a
heavy
chain variable region having the polypeptide sequence of SEQ ID NO:37; and a
light
chain variable region having the polypeptide sequence of SEQ ID NO:38.
[0093] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:100, 101, 102,
163, 164, and 165, respectively. In another embodiment, the isolated
monoclonal
antibody or antigen-binding fragment thereof comprises a heavy chain variable
region
having a polypeptide sequence at least 85%, preferably 90%, more preferably
95%
identical to SEQ ID NO:39, and a light chain variable region having a
polypeptide
sequence at least 85%, preferably 90%, more preferably 95% identical to SEQ ID
NO:40.
Preferably, the isolated monoclonal antibody or antigen-binding fragment
thereof
comprises a heavy chain variable region having the polypeptide sequence of SEQ
ID
.. NO 39; and a light chain variable region having the polypeptide sequence of
SEQ ID
NO:40.
29
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[0094] In one embodiment, the invention relates to an isolated monoclonal
antibody or
antigen-binding fragment thereof, comprising HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2 and LCDR3, having the polypeptide sequences of SEQ ID NOs:103, 104, 105,
166, 167, and 168, respectively. In another embodiment, the isolated
monoclonal
antibody or antigen-binding fragment thereof comprises a heavy chain variable
region
having a polypeptide sequence at least 85%, preferably 90%, more preferably
95%
identical to SEQ ID NO:41, and a light chain variable region having a
polypeptide
sequence at least 85%, preferably 90%, more preferably 95% identical to SEQ ID
NO:42.
Preferably, the isolated monoclonal antibody or antigen-binding fragment
thereof
comprises a heavy chain variable region having the polypeptide sequence of SEQ
ID
NO:41; and a light chain variable region having the polypeptide sequence of
SEQ ID
NO:42.
[0095] According to another particular aspect, the invention relates to an
isolated
monoclonal antibody or antigen-binding fragment thereof of the invention,
wherein the
antibody or antigen-binding fragment thereof is chimeric.
[0096] According to another particular aspect, the invention relates to an
isolated
monoclonal antibody or antigen-binding fragment thereof of the invention,
wherein the
antibody or antigen-binding fragment thereof is human or humanized.
[0097] According to another particular aspect, the invention relates to an
isolated
humanized monoclonal antibody or antigen-binding fragment thereof of the
invention,
wherein the isolated humanized antibody or antigen-binding fragment thereof
comprises:
(a) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:171, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:175;
(b) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:172, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:175;
(c) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:173, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:176; or
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
(d) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:174, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:176.
[0098] According to another particular aspect, the invention relates to an
isolated
monoclonal antibody or antigen-binding fragment thereof of the invention,
wherein the
antibody or antigen-binding fragment thereof is capable of blocking binding of
TIM-3 to
phosphatidylserine (PtdSer), TIM-3 to galectin-9 (Gal-9), TIM-3 to
carcinoembryonic
antigen cell adhesion molecule 1 (CEACAM1), and/or TIM-3 to high mobility
group
protein B1 (HMGB1).
[0099] In another general aspect, the invention relates to an isolated nucleic
acid
encoding a monoclonal antibody or antigen-binding fragment thereof of the
invention. It
will be appreciated by those skilled in the art that the coding sequence of a
protein can be
changed (e.g., replaced, deleted, inserted, etc.) without changing the amino
acid sequence
of the protein. Accordingly, it will be understood by those skilled in the art
that nucleic
acid sequences encoding monoclonal antibodies or antigen-binding fragments
thereof of
the invention can be altered without changing the amino acid sequences of the
proteins.
[00100] In another general aspect, the invention relates to a vector
comprising an
isolated nucleic acid encoding a monoclonal antibody or antigen-binding
fragment
thereof of the invention. Any vector known to those skilled in the art in view
of the
present disclosure can be used, such as a plasmid, a cosmid, a phage vector or
a viral
vector. In some embodiments, the vector is a recombinant expression vector
such as a
plasmid. The vector can include any element to establish a conventional
function of an
expression vector, for example, a promoter, ribosome binding element,
terminator,
enhancer, selection marker, and origin of replication. The promoter can be a
constitutive,
inducible or repressible promoter. A number of expression vectors capable of
delivering
nucleic acids to a cell are known in the art and can be used herein for
production of an
antibody or antigen-binding fragment thereof in the cell Conventional cloning
techniques
or artificial gene synthesis can be used to generate a recombinant expression
vector
according to embodiments of the invention.
[00101] In another general aspect, the invention relates to a host cell
comprising an
isolated nucleic acid encoding a monoclonal antibody or antigen-binding
fragment
31
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
thereof of the invention. Any host cell known to those skilled in the art in
view of the
present disclosure can be used for recombinant expression of antibodies or
antigen-
binding fragments thereof of the invention. In some embodiments, the host
cells are E.
coli TG1 or BL21 cells (for expression of, e.g., an scFv or Fab antibody), CHO-
DG44 or
CHO-Kl cells or HEK293 cells (for expression of, e.g., a full-length IgG
antibody).
According to particular embodiments, the recombinant expression vector is
transformed
into host cells by conventional methods such as chemical transfection, heat
shock, or
electroporation, where it is stably integrated into the host cell genome such
that the
recombinant nucleic acid is effectively expressed.
[00102] In another general aspect, the invention relates to a method of
producing a
monoclonal antibody or antigen-binding fragment thereof of the invention,
comprising
culturing a cell comprising a nucleic acid encoding the monoclonal antibody or
antigen-
binding fragment thereof under conditions to produce a monoclonal antibody or
antigen-
binding fragment thereof of the invention, and recovering the antibody or
antigen-binding
fragment thereof from the cell or cell culture (e.g., from the supernatant).
Expressed
antibodies or antigen-binding fragments thereof can be harvested from the
cells and
purified according to conventional techniques known in the art and as
described herein.
[00103] Pharmaceutical Compositions
[00104] In another general aspect, the invention relates to a pharmaceutical
composition, comprising an isolated monoclonal antibody or antigen-binding
fragment
thereof of the invention and a pharmaceutically acceptable carrier. The term
"pharmaceutical composition" as used herein means a product comprising an
antibody of
the invention together with a pharmaceutically acceptable carrier. Antibodies
of the
invention and compositions comprising them are also useful in the manufacture
of a
medicament for therapeutic applications mentioned herein.
[00105] As used herein, the term "carrier" refers to any excipient, diluent,
filler, salt,
buffer, stabilizer, solubilizer, oil, lipid, lipid containing vesicle,
microsphere, liposomal
encapsulation, or other material well known in the art for use in
pharmaceutical
formulations. It will be understood that the characteristics of the carrier,
excipient or
diluent will depend on the route of administration for a particular
application. As used
herein, the term "pharmaceutically acceptable carrier" refers to a non-toxic
material that
32
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
does not interfere with the effectiveness of a composition according to the
invention or
the biological activity of a composition according to the invention. According
to
particular embodiments, in view of the present disclosure, any
pharmaceutically
acceptable carrier suitable for use in an antibody pharmaceutical composition
can be used
in the invention.
[00106] The formulation of pharmaceutically active ingredients with
pharmaceutically
acceptable carriers is known in the art, e.g., Remington: The Science and
Practice of
Pharmacy (e.g. 21st edition (2005), and any later editions). Non-limiting
examples of
additional ingredients include: buffers, diluents, solvents, tonicity
regulating agents,
preservatives, stabilizers, and chelating agents. One or more pharmaceutically
acceptable
carriers can be used in formulating the pharmaceutical compositions of the
invention.
[00107] In one embodiment of the invention, the pharmaceutical composition is
a
liquid formulation. A preferred example of a liquid formulation is an aqueous
formulation, i.e., a formulation comprising water. The liquid formulation can
comprise a
solution, a suspension, an emulsion, a microemulsion, a gel, and the like. An
aqueous
formulation typically comprises at least 50% w/w water, or at least 60%, 70%,
75%, 80%,
85%, 90%, or at least 95% w/w of water.
[00108] In one embodiment, the pharmaceutical composition can be formulated as
an
injectable which can be injected, for example, via an injection device (e.g.,
a syringe or
an infusion pump). The injection can be delivered subcutaneously,
intramuscularly,
intraperitoneally, intravitreally, or intravenously, for example.
[00109] In another embodiment, the pharmaceutical composition is a solid
formulation,
e.g., a freeze-dried or spray-dried composition, which can be used as is, or
whereto the
physician or the patient adds solvents, and/or diluents prior to use. Solid
dosage forms
can include tablets, such as compressed tablets, and/or coated tablets, and
capsules (e.g.,
hard or soft gelatin capsules). The pharmaceutical composition can also be in
the form of
sachets, dragees, powders, granules, lozenges, or powders for reconstitution,
for example.
[00110] The dosage forms can be immediate release, in which case they can
comprise a
water-soluble or dispersible carrier, or they can be delayed release,
sustained release, or
modified release, in which case they can comprise water-insoluble polymers
that regulate
the rate of dissolution of the dosage form in the gastrointestinal tract or
under the skin.
33
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[00111] In other embodiments, the pharmaceutical composition can be delivered
intranasally, intrabuccally, or sublingually.
[00112] The pH in an aqueous formulation can be between pH 3 and pH 10. In one
embodiment of the invention, the pH of the formulation is from about 7.0 to
about 9.5. In
another embodiment of the invention, the pH of the formulation is from about
3.0 to
about 7Ø
[00113] In another embodiment of the invention, the pharmaceutical composition
comprises a buffer. Non-limiting examples of buffers include: arginine,
aspartic acid,
bicine, citrate, disodium hydrogen phosphate, fumaric acid, glycine,
glycylglycine,
histidine, lysine, maleic acid, malic acid, sodium acetate, sodium carbonate,
sodium
dihydrogen phosphate, sodium phosphate, succinate, tartaric acid, tricine, and
tris(hydroxymethyl)-aminomethane, and mixtures thereof. The buffer can be
present
individually or in the aggregate, in a concentration from about 0.01 mg/ml to
about 50
mg/ml, for example from about 0.1 mg/ml to about 20 mg/ml. Pharmaceutical
compositions comprising each one of these specific buffers constitute
alternative
embodiments of the invention.
[00114] In another embodiment of the invention, the pharmaceutical composition
comprises a preservative. Non-limiting examples of preservatives include:
benzethonium
chloride, benzoic acid, benzyl alcohol, bronopol, butyl 4-hydroxybenzoate,
chlorobutanol,
chlorocresol, chlorohexidine, chlorphenesin, o-cresol, m-cresol, p-cresol,
ethyl 4-
hydroxybenzoate, imidurea, methyl 4-hydroxybenzoate, phenol, 2-phenoxyethanol,
2-
phenylethanol, propyl 4-hydroxybenzoate, sodium dehydroacetate, thiomerosal,
and
mixtures thereof. The preservative can be present individually or in the
aggregate, in a
concentration from about 0.01 mg/ml to about 50 mg/ml, for example from about
0.1
mg/ml to about 20 mg/ml. Pharmaceutical compositions comprising each one of
these
specific preservatives constitute alternative embodiments of the invention.
[00115] In another embodiment of the invention, the pharmaceutical composition
comprises an isotonic agent. Non-limiting examples of the embodiment include a
salt
(such as sodium chloride), an amino acid (such as glycine, histidine,
arginine, lysine,
isoleucine, aspartic acid, tryptophan, and threonine), an alditol (such as
glycerol, 1,2-
propanediol propyleneglycol), 1,3-propanediol, and 1,3-butanediol),
polyethyleneglycol
34
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
(e.g. PEG400), and mixtures thereof. Another example of an isotonic agent
includes a
sugar. Non-limiting examples of sugars can be mono-, di-, or polysaccharides,
or water-
soluble glucans, including for example fructose, glucose, mannose, sorbose,
xylose,
maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin,
cyclodextrin, alpha and
beta- HPCD, soluble starch, hydroxyethyl starch, and sodium
carboxymethylcellulose.
Another example of an isotonic agent is a sugar alcohol, wherein the term
"sugar
alcohol" is defined as a C(4-8) hydrocarbon having at least one -OH group. Non-
limiting
examples of sugar alcohols include mannitol, sorbitol, inositol, galactitol,
dulcitol, xylitol,
and arabitol. The isotonic agent can be present individually or in the
aggregate, in a
concentration from about 0.01 mg/ml to about 50 mg/ml, for example from about
0.1
mg/ml to about 20 mg/ml. Pharmaceutical compositions comprising each one of
these
specific isotonic agents constitute alternative embodiments of the invention.
[00116] In another embodiment of the invention, the pharmaceutical composition
comprises a chelating agent. Non-limiting examples of chelating agents include
citric
acid, aspartic acid, salts of ethylenediaminetetraacetic acid (EDTA), and
mixtures thereof.
The chelating agent can be present individually or in the aggregate, in a
concentration
from about 0.01 mg/ml to about 50 mg/ml, for example from about 0.1 mg/ml to
about 20
mg/ml. Pharmaceutical compositions comprising each one of these specific
chelating
agents constitute alternative embodiments of the invention.
[00117] In another embodiment of the invention, the pharmaceutical composition
comprises a stabilizer. Non-limiting examples of stabilizers include one or
more
aggregation inhibitors, one or more oxidation inhibitors, one or more
surfactants, and/or
one or more protease inhibitors.
[00118] In another embodiment of the invention, the pharmaceutical composition
comprises a stabilizer, wherein said stabilizer is carboxy-/hydroxycellulose
and derivates
thereof (such as HPC, HPC-SL, HPC-L and HPMC), cyclodextrins, 2-
methylthioethanol,
polyethylene glycol (such as PEG 3350), polyvinyl alcohol (PVA), polyvinyl
pyrrolidone,
salts (such as sodium chloride), sulphur-containing substances such as
monothioglycerol),
or thioglycolic acid. The stabilizer can be present individually or in the
aggregate, in a
concentration from about 0.01 mg/ml to about 50 mg/ml, for example from about
0.1
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
mg/ml to about 20 mg/ml. Pharmaceutical compositions comprising each one of
these
specific stabilizers constitute alternative embodiments of the invention.
[00119] In further embodiments of the invention, the pharmaceutical
composition
comprises one or more surfactants, preferably a surfactant, at least one
surfactant, or two
different surfactants. The term "surfactant" refers to any molecules or ions
that are
comprised of a water-soluble (hydrophilic) part, and a fat-soluble
(lipophilic) part. The
surfactant can, for example, be selected from the group consisting of anionic
surfactants,
cationic surfactants, nonionic surfactants, and/or zwitterionic surfactants.
The surfactant
can be present individually or in the aggregate, in a concentration from about
0.1 mg/ml
to about 20 mg/ml. Pharmaceutical compositions comprising each one of these
specific
surfactants constitute alternative embodiments of the invention.
[00120] In a further embodiment of the invention, the pharmaceutical
composition
comprises one or more protease inhibitors, such as, e.g., EDTA, and/or
benzamidine
hydrochloric acid (HCl). The protease inhibitor can be present individually or
in the
aggregate, in a concentration from about 0.1 mg/ml to about 20 mg/ml.
Pharmaceutical
compositions comprising each one of these specific protease inhibitors
constitute
alternative embodiments of the invention.
[00121] In another general aspect, the invention relates to a method of
producing a
pharmaceutical composition comprising a monoclonal antibody or antigen-binding
fragment thereof of the invention, comprising combining a monoclonal antibody
or
antigen-binding fragment thereof with a pharmaceutically acceptable carrier to
obtain the
pharmaceutical composition.
[00122] Methods of Use
[00123] In another general aspect, the invention relates to a method of
blocking the
binding of TIM-3 to phosphatidylserine (PtdSer), a method of blocking the
binding of
TIM-3 to galectin-9, a method of blocking the binding of TIM-3 to
carcinoembryonic
antigen cell adhesion molecule 1 (CEACAM1), or a method of blocking the
binding of
TIM-3 to high mobility group protein B1 (HMGB1), the method comprising
administering to the subject a pharmaceutical composition of the invention.
[00124] The functional activity of antibodies and antigen-binding fragments
thereof
that bind TIM-3 can be characterized by methods known in the art and as
described
36
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
herein. Methods for characterizing antibodies and antigen-binding fragments
thereof that
bind TIM-3 include, but are not limited to, affinity and specificity assays
including
Biacore, ELISA, and OctetRed analysis; receptor ligand binding assays to
detect blocking
of the binding of TIM-3 to PtdSer, galectin-9, CEACAM1, and/or HMGB1; the
functional effect of inhibition of PtdSer-TIM-3 interaction by an anti-TIM-3
mAb can be
detected in a cell-based phagocytosis assay where TIM-3 expressing macrophages
are
incubated with cells undergoing apoptosis (and thereby expressing PtdSer) and
the
mAb's blocking of the PtdSer-TIM-3 interaction leads to increased
phagocytosis. The
functional effect of inhibition of Gal-9-TIM-3 interaction by an anti-TIM-3
mAb can be
detected in a cell-based assay where IFN-y secretion and cell killing are
induced as a
result of the mAb's blocking of the binding of Gal-9 on AML cells to TIM-3 on
NK cells.
The functional effect of inhibition of HMGB1-TIM-3 interaction by an anti-TIM-
3 mAb
can be detected in a cell-based assay where TIM-3 expressing cells are
incubated with B-
DNA and the mAb's blocking of the HMGB1-TIM-3 interaction leads to increased
INF-
131 production. The functional activity of an anti-TIM-3 mAb can also be
assessed in a
Mixed Lymphocyte Reaction (MLR) assay where dendritic cells and CD4+ cells
from
different donors are mixed in the presence of the mAb and stimulation of
cytokine
secretion is measured. According to particular embodiments, the methods for
characterizing antibodies and antigen-binding fragments thereof that bind TIM-
3 include
those described below.
[00125] In another general aspect, the invention relates to a method of
treating a cancer
in a subject in need thereof, comprising administering to the subject a
pharmaceutical
composition of the invention. The cancer can, for example, be selected from
but not
limited to, a lung cancer, a gastric cancer, a colon cancer, a hepatocellular
carcinoma, a
renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a
breast
cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a
pancreatic cancer,
a glioma, a glioblastoma, and other solid tumors, and a non-Hodgkin's lymphoma
(NHL),
an acute lymphocytic leukemia (ALL), a chronic lymphocytic leukemia (CLL), a
chronic
myelogenous leukemia (CML), a multiple myeloma (MM), an acute myeloid leukemia
(AML), and other liquid tumors.
37
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[00126] In another general aspect, the invention relates to a method of
treating an
infectious disease in a subject in need thereof, comprising administering to
the subject a
pharmaceutical composition of the invention
[00127] In another general aspect, the invention relates to a method of
treating an
inflammatory disease in a subject in need thereof, comprising administering to
the subject
a pharmaceutical composition of the invention.
[00128] In another general aspect, the invention relates to a method of
treating an
autoimmune disease in a subject in need thereof, comprising administering to
the subject
a pharmaceutical composition of the invention.
[00129] In another general aspect, the invention relates to a method of
treating a
metabolic disease in a subject in need thereof, comprising administering to
the subject a
pharmaceutical composition of the invention
[00130] According to embodiments of the invention, the pharmaceutical
composition
comprises a therapeutically effective amount of the anti-TIM-3 antibody or
antigen-
binding fragment thereof. As used herein, the term "therapeutically effective
amount"
refers to an amount of an active ingredient or component that elicits the
desired biological
or medicinal response in a subject. A therapeutically effective amount can be
determined
empirically and in a routine manner, in relation to the stated purpose.
[00131] As used herein with reference to anti-TIM-3 antibodies or antigen-
binding
fragments thereof, a therapeutically effective amount means an amount of the
anti-TIM-3
antibody or antigen-binding fragment thereof that modulates an immune response
in a
subject in need thereof Also as used herein with reference to anti-TIM-3
antibodies or
antigen-binding fragments thereof, a therapeutically effective amount means an
amount
of the anti-TIM-3 antibody or antigen-binding fragment thereof that results in
treatment
of a disease, disorder, or condition; prevents or slows the progression of the
disease,
disorder, or condition; or reduces or completely alleviates symptoms
associated with the
disease, disorder, or condition
[00132] According to particular embodiments, the disease, disorder or
condition to be
treated is cancer, preferably a cancer selected from the group consisting of a
lung cancer,
a gastric cancer, a colon cancer, a hepatocellular carcinoma, a renal cell
carcinoma, a
bladder urothelial carcinoma, a metastatic melanoma, a breast cancer, an
ovarian cancer,
38
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
a cervical cancer, a head and neck cancer, a pancreatic cancer, a glioma, a
glioblastoma,
and other solid tumors, and a non-Hodgkin's lymphoma (NHL), an acute
lymphocytic
leukemia (ALL), a chronic lymphocytic leukemia (CLL), a chronic myelogenous
leukemia (CML), a multiple myeloma (MM), an acute myeloid leukemia (AML), and
other liquid tumors. According to other particular embodiments, the disease,
disorder or
condition to be treated is an infectious disease, an inflammatory disease, an
immune
disease, an autoimmune disease, and/or a metabolic disease.
[00133] According to particular embodiments, a therapeutically effective
amount refers
to the amount of therapy which is sufficient to achieve one, two, three, four,
or more of
the following effects: (i) reduce or ameliorate the severity of the disease,
disorder or
condition to be treated or a symptom associated therewith; (ii) reduce the
duration of the
disease, disorder or condition to be treated, or a symptom associated
therewith; (iii)
prevent the progression of the disease, disorder or condition to be treated,
or a symptom
associated therewith; (iv) cause regression of the disease, disorder or
condition to be
treated, or a symptom associated therewith; (v) prevent the development or
onset of the
disease, disorder or condition to be treated, or a symptom associated
therewith; (vi)
prevent the recurrence of the disease, disorder or condition to be treated, or
a symptom
associated therewith; (vii) reduce hospitalization of a subject having the
disease, disorder
or condition to be treated, or a symptom associated therewith; (viii) reduce
hospitalization length of a subject having the disease, disorder or condition
to be treated,
or a symptom associated therewith; (ix) increase the survival of a subject
with the disease,
disorder or condition to be treated, or a symptom associated therewith; (xi)
inhibit or
reduce the disease, disorder or condition to be treated, or a symptom
associated therewith
in a subject; and/or (xii) enhance or improve the prophylactic or therapeutic
effect(s) of
another therapy.
[00134] The therapeutically effective amount or dosage can vary according to
various
factors, such as the disease, disorder or condition to be treated, the means
of
administration, the target site, the physiological state of the subject
(including, e.g., age,
body weight, health), whether the subject is a human or an animal, other
medications
administered, and whether the treatment is prophylactic or therapeutic
Treatment
dosages are optimally titrated to optimize safety and efficacy.
39
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[00135] According to particular embodiments, the compositions described herein
are
formulated to be suitable for the intended route of administration to a
subject. For
example, the compositions described herein can be formulated to be suitable
for
intravenous, subcutaneous, or intramuscular administration.
[00136] As used herein, the terms "treat," "treating," and "treatment" are all
intended to
refer to an amelioration or reversal of at least one measurable physical
parameter related
to a cancer, an infectious disease, disorder or condition, an immune disease,
disorder or
condition, an autoimmune disease, disorder or condition, an inflammatory
disease,
disorder or condition, and/or a metabolic disease, disorder or condition,
which is not
necessarily discernible in the subject, but can be discernible in the subject.
The terms
"treat," "treating," and "treatment," can also refer to causing regression,
preventing the
progression, or at least slowing down the progression of the disease,
disorder, or
condition. In a particular embodiment, "treat," "treating," and "treatment"
refer to an
alleviation, prevention of the development or onset, or reduction in the
duration of one or
more symptoms associated with the disease, disorder, or condition, such as a
tumor or
more preferably a cancer. In a particular embodiment, "treat," "treating," and
"treatment"
refer to prevention of the recurrence of the disease, disorder, or condition.
In a particular
embodiment, "treat," "treating," and "treatment" refer to an increase in the
survival of a
subject having the disease, disorder, or condition. In a particular
embodiment, "treat,"
"treating," and "treatment" refer to elimination of the disease, disorder, or
condition in
the subject.
[00137] According to particular embodiments, a composition used in the
treatment of a
cancer, an infectious disease, disorder or condition, an immune disease,
disorder or
condition, an autoimmune disease, disorder or condition, a metabolic disease,
disorder or
condition, and/or an inflammatory disease, disorder or condition can be used
in
combination with another treatment. For cancer treatment, the composition can
be used
in combination with another treatment including, but not limited to, a
chemotherapy, an
anti-CD20 mAb, an anti-CTLA-4 antibody, an anti-LAG-3 mAb, an anti-EGFR mAb,
an
anti-HER-2 mAb, an anti-CD19 mAb, an anti-CD33 mAb, an anti-CD73 mAb, an anti-
CD47 mAb, an anti-DLL-3 mAb, an anti-apelin mAb, an anti-TIP-1 mAb, an anti-
CLDN18.2 mAb, an anti-FOLR1 mAb, an anti-PD-Li antibody, an anti-PD-1
antibody, a
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
PD-1/PD-L1 therapy, other immuno-oncology drugs, an antiangiogenic agent, a
radiation
therapy, an antibody-drug conjugate (ADC), a targeted therapy, or other
anticancer drugs.
[00138] As used herein, the term "in combination," in the context of the
administration
of two or more therapies to a subject, refers to the use of more than one
therapy. The use
of the term "in combination" does not restrict the order in which therapies
are
administered to a subject. For example, a first therapy (e.g., a composition
described
herein) can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes,
45 minutes,
1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72
hours, 96
hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12
weeks
before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30
minutes, 45
minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48
hours, 72
hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks,
or 12
weeks after) the administration of a second therapy to a subject.
[00139] In another general aspect, the invention relates to a method of
determining a
level of TIM-3 in a subject, comprising (a) obtaining a sample from the
subject; (b)
contacting the sample with an antibody or antigen-binding fragment thereof of
the
invention; and (c) determining the level of TIM-3 in the subject. In certain
embodiments,
the sample is a tissue or blood sample. The tissue sample can, for example, be
a cancer
tissue sample. The blood sample can, for example, comprise cancer cells.
[00140] As used herein, "sample" refers to a biological sample isolated from a
subject
and can include, but is not limited to, whole blood, serum, plasma, blood
cells,
endothelial cells, tissue biopsies (e.g., a cancer tissue, a hepatic tissue,
etc.), lymphatic
fluid, ascites fluid, interstitial fluid, bone marrow, cerebrospinal fluid,
saliva, mucous,
sputum, sweat, urine, or any other secretion, excretion, or other bodily
fluids. A "blood
sample" refers to whole blood or any fraction thereof, including blood cells,
serum, and
plasma. A "blood sample" can, for example, comprise cancer cells.
[00141] In certain embodiments, the level of TIM-3 in the subject can be
determined
utilizing assays selected from, but not limited to, a Western blot assay, an
ELISA assay, a
FACS assay, and/or an immunohistochemistry (IHC). Relative protein levels can
be
determined by utilizing Western blot analysis, FACS assay, and
immunohistochemistry
(IHC), and absolute protein levels can be determined by utilizing an ELISA
assay. When
41
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
determining the relative levels of TIM-3, the levels of TIM-3 can be
determined between
at least two samples, e.g., between samples from the same subject at different
time points,
between samples from different tissues in the same subject, and/or between
samples from
different subjects. Alternatively, when determining absolute levels of TIM-3,
such as by
an ELISA assay, the absolute level of TIM-3 in the sample can be determined by
creating
a standard for the ELISA assay prior to testing the sample. A person skilled
in the art
would understand which analytical techniques to utilize to determine the level
of TIM-3
in a sample from the subject utilizing the antibodies or antigen-binding
fragments thereof
of the invention.
[00142] Utilizing methods of determining a level of TIM-3 in a sample from a
subject
can lead to the diagnosis of abnormal (elevated, reduced, or insufficient) TIM-
3 levels in
a disease and making appropriate therapeutic decisions. Such a disease can be
selected
from, but not limited to, a cancer, preferably a cancer selected from the
group consisting
of lung cancer, gastric cancer, colon cancer, hepatocellular carcinoma, renal
cell
carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer,
ovarian
cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma,
glioblastoma,
and other solid tumors, and non-Hodgkin's lymphoma (NHL), acute lymphocytic
leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myelogenous
leukemia
(CML), multiple myeloma (MM), acute myeloid leukemia (AML), and other liquid
tumors, an inflammatory disease, an infectious disease, metabolic diseases, an
immune
disease, and/or an autoimmune disease.
EMBODIMENTS
[00143] The invention provides also the following non-limiting embodiments.
[00144] Embodiment 1 is an isolated monoclonal antibody or antigen-binding
fragment
thereof comprising a heavy chain complementarity determining region 1 (HCDR1),
HCDR2, HCDR3, a light chain complementarity determining region 1 (LCDR1),
LCDR2,
and LCDR3, having the polypeptide sequences of
(1) SEQ ID NOs:43, 44, 169, 106, 107, and 170, respectively;
(2) SEQ ID NOs:55, 56, 57, 118, 119, and 120, respectively;
(3) SEQ ID NOs:58, 59, 60, 121, 122, and 123, respectively;
42
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
(4) SEQ ID NOs:61, 62, 63, 124, 125, and 126, respectively;
(5) SEQ ID NOs:64, 65, 66, 127, 128, and 129, respectively;
(6) SEQ ID NOs:67, 68, 69, 130, 131, and 132, respectively;
(7) SEQ ID NOs:70, 71, 72, 133, 134, and 135, respectively;
(8) SEQ ID NOs:73, 74, 75, 136, 137, and 138, respectively;
(9) SEQ ID NOs:76, 77, 78, 139, 140, and 141, respectively;
(10) SEQ ID NOs:79, 80, 81, 142, 143, and 144, respectively;
(11) SEQ ID NOs:82, 83, 84, 145, 146, and 147, respectively;
(12) SEQ ID NOs:85, 86, 87, 148, 149, and 150, respectively;
(13) SEQ ID NOs:88, 89, 90, 151, 152, and 153, respectively;
(14) SEQ ID NOs:91, 92, 93, 154, 155, and 156, respectively;
(15) SEQ ID NOs:94, 95, 96, 157, 158, and 159, respectively;
(16) SEQ ID NOs:97, 98, 99, 160, 161, and 162, respectively;
(17) SEQ ID NOs:100, 101, 102, 163, 164, and 165, respectively; or
(18) SEQ ID NOs:103, 104, 105, 166, 167, and 168, respectively;
wherein the antibody or antigen-binding fragment thereof specifically binds
TIM-3,
preferably human TIM-3.
[00145] Embodiment 2 is the isolated monoclonal antibody or antigen-binding
fragment of embodiment 1, comprising a heavy chain variable region having a
polypeptide sequence at least 95% identical to SEQ ID NO:1, 3, 5, 7, 9, 11,
13, 15, 17, 19,
21, 23, 25, 27, 29, 31, 33, 35, 37, 39, or 41 or a light chain variable region
having a
polypeptide sequence at least 95% identical to SEQ ID NO:2, 4, 6, 8, 10, 12,
14, 16, 18,
20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, or 42.
[00146] Embodiment 3 is the isolated monoclonal antibody or antigen-binding
fragment of embodiment 1 or 2, comprising
(a) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:1, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:2;
(b) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:3, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:4;
43
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
(c) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:5, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:6;
(d) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:7, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:8;
(e) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:9, and a light chain variable region having the polypeptide sequence of SEQ
ID NO:10;
(0 a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:11, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:12;
(g) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:13, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:14;
(h) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:15, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:16;
(i) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:17, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:18;
(j) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:19, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:20;
(k) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:21, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:22;
(1) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:23, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:24;
44
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
(m) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:25, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:26;
(n) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:27, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:28;
(o) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:29, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:30;
(p) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:31, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:32;
(q) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:33, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:34;
(r) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:35, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:36;
(s) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:37, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:38;
(t) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:39, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:40; or
(u) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:41, and a light chain variable region having the polypeptide sequence of
SEQ
ID NO:42.
[00147] Embodiment 4 is the isolated monoclonal antibody or antigen-binding
fragment of any of embodiments 1 to 3, wherein the antibody or antigen-binding
fragment thereof is chimeric.
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[00148] Embodiment 5 is the isolated monoclonal antibody or antigen-binding
fragment of any of embodiments 1 to 4, wherein the antibody or antigen-binding
fragment thereof is human or humanized.
[00149] Embodiment 6 is the isolated monoclonal antibody or antigen-binding
fragment of embodiment 5, wherein the antibody or antigen-binding fragment
thereof
comprises:
(a) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:171, and a light chain variable region having the polypeptide sequence of
SEQ ID NO:175;
(b) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:172, and a light chain variable region having the polypeptide sequence of
SEQ ID NO:175;
(c) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:173, and a light chain variable region having the polypeptide sequence of
SEQ ID NO:176; or
(d) a heavy chain variable region having the polypeptide sequence of SEQ ID
NO:174, and a light chain variable region having the polypeptide sequence of
SEQ ID NO:176.
[00150] Embodiment 7 is the isolated monoclonal antibody or antigen-binding
fragment of any of embodiments 1 to 6, wherein the antibody or antigen-binding
fragment thereof is capable of blocking binding of TIM-3 to phosphatidylserine
(PtdSer),
TIM-3 to galectin-9 (Gal-9), TIM-3 to carcinoembryonic antigen cell adhesion
molecule
1 (CEACAM1), and/or TIM-3 to high mobility group protein B1 (HMGB1).
[00151] Embodiment 8 is an isolated nucleic acid encoding the monoclonal
antibody or
antigen-binding fragment of any of embodiments 1 to 7.
[00152] Embodiment 9 is a vector comprising the isolated nucleic acid of
embodiment
8.
[00153] Embodiment 10 is a host cell comprising the vector of embodiment 9.
[00154] Embodiment 11 is a pharmaceutical composition, comprising the isolated
monoclonal antibody or antigen-binding fragment of any of embodiments 1 to 7
and a
pharmaceutically acceptable carrier.
46
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[00155] Embodiment 12 is a method of blocking binding of TIM-3 to
phosphatidylserine (PtdSer) in a subject in need thereof, comprising
administering to the
subject the pharmaceutical composition of embodiment 11.
[00156] Embodiment 13 is a method of blocking binding of TIM-3 to galectin-9
(Gal-9)
in a subject in need thereof, comprising administering to the subject the
pharmaceutical
composition of embodiment 11.
[00157] Embodiment 14 is a method of blocking binding of TIM-3 to
carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) in a subject in
need
thereof, comprising administering to the subject the pharmaceutical
composition of
embodiment 11
[00158] Embodiment 15 is a method of blocking binding of TIM-3 to high
mobility
group protein B1 (HMGB1) in a subject in need thereof, comprising
administering to the
subject the pharmaceutical composition of embodiment 11.
[00159] Embodiment16 is a method of treating cancer in a subject in need
thereof,
comprising administering to the subject the pharmaceutical composition of
embodiment
11.
[00160] Embodiment 17 is a method of treating an infectious disease in a
subject in
need thereof, comprising administering to the subject the pharmaceutical
composition of
embodiment 11
.. [00161] Embodiment 18 is a method of treating an inflammatory disease in a
subject in
need thereof, comprising administering to the subject the pharmaceutical
composition of
embodiment 11
[00162] Embodiment 19 is a method of treating an autoimmune disease in a
subject in
need thereof, comprising administering to the subject the pharmaceutical
composition of
embodiment 11
[00163] Embodiment 20 is a method of treating a metabolic disease in a subject
in need
thereof, comprising administering to the subject the pharmaceutical
composition of
embodiment 11
[00164] Embodiment 21 is a method of producing the monoclonal antibody or
antigen-
binding fragment of any of embodiments 1 to 7, comprising culturing a cell
comprising a
nucleic acid encoding the monoclonal antibody or antigen-binding fragment
under
47
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
conditions to produce the monoclonal antibody or antigen-binding fragment, and
recovering the antibody or antigen-binding fragment from the cell or culture.
[00165] Embodiment 22 is a method of producing a pharmaceutical composition
comprising the monoclonal antibody or antigen-binding fragment of any of
embodiments
.. 1 to 7, comprising combining the monoclonal antibody or antigen-binding
fragment with
a pharmaceutically acceptable carrier to obtain the pharmaceutical
composition.
[00166] Embodiment 23 is a method of determining a level of TIM-3 in a
subject,
comprising (a) obtaining a sample from the subject; (b) contacting the sample
with an
antibody or antigen-binding fragment thereof of the invention; and (c)
determining the
level of TIM-3 in the subject.
[00167] Embodiment 24 is the method of embodiment 23, wherein the sample is a
tissue sample.
[00168] Embodiment 25 is the method of embodiment 24, wherein the tissue
sample is
a cancer tissue sample.
[00169] Embodiment 26 is the method of embodiment 23, wherein the sample is a
blood sample.
EXAMPLES
[00170] Example 1: Identification of Anti-TIM-3 monoclonal antibodies
[00171] Mice were immunized with Fc-tagged human and cynomolgus TIM-3
extracellular domain (ECD) proteins and adjuvant. Plasma titer was determined
by
enzyme linked immunosorbent assay (ELISA). After euthanization, spleens and
lymph
nodes were collected to produce hybridomas. Hybridomas were grown in 384-well
tissue
culture plates and supernatants from individual wells were screened by ELISA
to identify
positive binders for human and cynomolgus TIM-3 ECD proteins. Positive
supernatants
were also screened for blocking of phosphatidylserine binding to TIM-3
recombinant
protein and binding to native TIM-3 protein by FACS analysis on TIM-3-
expressing
HEK293 cells. Positive clones were isolated and sequenced.
[00172] Sequences of heavy and light chain variable regions for anti-TIM-3
monoclonal antibodies are provided in Tables 1 and 2, and the CDR regions for
the anti-
48
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
TIM-3 monoclonal antibodies are provided in Tables 3 and 4. The CDR regions
for the
anti-TIM-3 monoclonal antibodies were determined utilizing the IMGT method.
Table 1: Sequences of heavy chain variable regions for anti-TIM-3 monoclonal
antibodies (mAb s)
mAb clones VH
20-L10-A QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKVLKWMVWIN
TYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARDAMDYWG
QGTSVTVSS (SEQ ID NO:1)
15-L23-A QIQLVQSGPELKKPGETVKISCRASGYTFTNYGMNWVKQAPGKGLKWMVWIN
TYTGEPTFADDFKGRFAF SLETSASTAYLQIINLKNEDTATYFCARDTMDYWGQ
GTSVTVS S (SEQ ID NO:3)
8-F3-A QIQLVQSGPELKKPGETVKISCKAS GYTFTNYGMNWVKQAPGKGLKWMAWIN
TYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARDLEDYWGQ
GTTLTVSS (SEQ ID NO:5)
7-P15-A QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWIN
TYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARDLMDYWG
QGTTLTVSS (SEQ ID NO:7)
18-Ni -A QVQLQQPGAELVRPGVSVKLSCKASGYTFTSYWMHWIKQRPEQGLERIGEINPS
NGGTNYNEKFKNKATLTVDK S S S TAYMQL S SLT SED S AVYYCARSYYTYD AID
YWGQGTSVTVS S (SEQ ID NO:9)
18-022-A EVQLQQSGPELVKPGASVKVSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINP
YND VTKYNEKFKGKATLT SDK S S S TAYMEL S SLTSED SAVYY CARS SDYDDGH
WYFDVWGAGTTVTVSS (SEQ ID NO:11)
16-L3 -A QVQLQQ S GPELVKPGAS VKMS CKAS GYTFTSYYIHWVKQRPGQGLEWIGWIYP
GD GS TKYNEKFKGKTTLTADK S S S TAYMLL S SLT SED SAIYFCATDRYDVAYWG
QGTLVTVSA (SEQ ID NO:13)
16-K5-A QVQLQQSGAELVKPGASVKLS CKAS GYTFT S SD INWVRQRPEQ GLEWIGWIFP G
D GS TKYNEKFKGKATLTTDK S S STAYMQL SRLTSED S AVYF CARGLDYWGQ GT
TLTVSS (SEQ ID NO:15)
19-A14-A D VQLQ GS GP GL VKP SQ SL SL TCTVTGY SIT SDYAWNWIRQFP GNILEWMGYISY S
GSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARDGRYDYYAMDY
WGQGTSVTVSS (SEQ ID NO:17)
2-K2-A QVQLQQSGAELAKPGASVKMSCKASGYTFTTYWMEIWVKQRPGQGLEWIGYIN
PSTGYTEYNQKFKDKSTLTADKSSSTAYMQLSSLTSEDSAVYYCANDHEGGFAY
WGQGTLVTVSA (SEQ ID NO:19)
6-H6-A EVQLQQFGAELVKPGASVKISCKASGYTFTDYNMDWVKQ SHGKSLEWIGDIDP
NYDSTTYNQKFKGKATLTVDKSSSTAYMELRSLTSEDTAVYYCARGGHYRYDG
YYAMDYWGQGTSVTVSS (SEQ ID NO:21)
1-A 19-A EVQLQQFGAELVKP GA S VKI S CKA S GYTFTDYNMD WVKQ SHGKSLEWIGDIDP
NYDITTYNQKFKGKATLTVDKS S STAYMELRSLTSEDTAVYYCARGGHYRYD G
YYALDYWGQGTSVTVSS (SEQ ID NO:23)
10-015-A QVQLQQ S GADLVRP GA S VKL SCKALGYTFTDYEMHWVKQTPVHGLEWIGAIHP
GSGGTAYNQKFKGKATLTADKSS STAYMEL SSLTSEDSAVYFCSRSYYRYTGYF
DVWGAGTTVTVS S (SEQ ID NO:25)
6-113-A EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMNWVKQSNGKSLEWIGNIDPY
YGVTSYNQKFKGKATLTVDKSSSTAYMQLKSLTSED S AVYYCA SY SLTYD GYY
PFAYWGQGTLVTVSA (SEQ ID NO:27)
5-K4-A EVQLQQSGPELVKTGASVKISCKASGYSFTAYYIHWVKQSHGKSLEWIGHIS CFN
GATSYNQKFKGKATFTVDTSS STAYMQFNSLTSED SAVYYCARRGDFDRPEFAY
WGQGTLVTVSA (SEQ ID NO:29)
49
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
12-G18-A DVQLQESGPGLVKP S Q SL SLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYISY
SGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTIGDTATYYCASNYRYDYWFFGV
WGAGTTVTVSS (SEQ ID NO:31)
10-M21-A DVQLQESGPTLVKPSQTLSLTCSVTGD SIT SGYWNWIRKFPGNKLEYMGYISYS G
STYYNPSLKSRISIIRDTSKNQYYLQLNSVT IEDTATYYCVSGNHFDYWGQG Fit
TVS S (SEQ ID NO:33)
12-M1 1-A SQVQLQQSGAELAKPGASVKMSCKASGYFTSYWMHWVKQRPGQGLEWIGYIN
PITGY l'EYNQKFKDKATLTADKS S STAYMQL SRL TSED SAVYYCARGVENFDYL
YAMDYWGQGASVTVSS (SEQ ID NO:35)
5-C11-A EVQLVE S GGGLVKPGG SLKL S CAAS GFTF SDFYMYWVRQTPEKRLEWVATISD
GGSYTYYPDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCASGYYYGSDY
VMDYWGQGTSVTVSS (SEQ ID NO:37)
16-J5-A DVQLVESGGGLVQPGGSRKLSCAASGFTFS SFGMNWVRQAPEKGLEWVAYISS
GS STIYYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARWGRWADFD
YWGQGTTLTVSS (SEQ ID NO:39)
7-N2-A QVQLKESGPGLVAPSQSLSITCTVSGFSLTGFGVNWVRQPPGKGLEWLGMIWGD
GSTDYNSTLKSRL S ISKDNSKSQVFLKMNSLQTDDTARYYCARDYYGYVGNAM
DYWGQGTSVTVSS (SEQ ID NO:41)
VH: heavy chain variable region
Table 2: Sequences of light chain variable regions for anti-TIM-3 mAbs
mAb clones VL
20-L10-A DVVMTQTPL SLPVSLGDQASIS CRS SQ SLVH SNGNTYLHWYLQKPGQ SPKLLIY
KVSNRFS GVPDRFSGS GS GTDFTLKISRVEAEDL GVYFC SQNTHVPWTFGGGTK
LEIK (SEQ ID NO:2)
15-L23 -A DIVMTQTPLSLPVSLGDQASIS CRS SQ SLVHSNGNTYLHWYLQKPGQSPKLLIYK
VSNRFS GVPDRF S GS GS GTDFTLKISRVEAEDLGVYFCSQNTHVPWTFGGGTKLE
IK (SEQ ID NO:4)
8-F3-A DVVMTQTPL SLPVSLGDQASIS CRS SQSLVHSNGNTYLHWYLQKPGQSPKLLIY
KVSNRFS GVPDRFSGS G S GTDFTLKISRVEAEDLGVYFC SQTTHVPWTFGGGTKL
EIK (SEQ ID NO:6)
7-P15-A DVVMTQTPL SLPVSLGDQASIS CRS SQ SLVH SNGNTYLHWYLQKPGQ SPKLLIY
KVSNRFS GVPDRFSGSGSGTDFTLKITRVEAEDLGVYFCSQ SIHVPYTFGGGTKL
EIK (SEQ ID NO:8)
18-N1-A DIVMSQ SP S SLAVSAGEKVTMS CKS SQ SLLNSRTRKNYLAWYQQKPGQ SPKLLI
YWA STRE S GVPDRFTGS GS GTDFTLTIS SVQAEDLAVYYCKQ SYNLYTFGGGTK
LEIK (SEQ ID NO:10)
18-022-A DIVLTQSPASLAVSLGQRATISCKASQSVDYDGESYMNWYQQKPGQPPKLLIYV
ASNLES GIPVRF S GS GSGTDFTLNIHPVEEEDAATYYCQQ SNEDPTWTFGGGTKL
EIK (SEQ ID NO:12)
16-L3 -A EIVLTQSPALMAASPGEKVTITCSVSSSIS SSNLHWYQQKSETSPKPWIYGTSNLA
SGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWS SYPLTFGAGTKLELK
(SEQ ID NO:14)
16-K5-A DIKMTQ SPS SMYASLGERVTITCKASQDINSYLGWFQQKPGKSPKTLIYRADRLV
DGVPSRF SGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPLTFGAGTKLELK
(SEQ ID NO:16)
19-A14-A DIVLTQSPASLAVSLGQRATIS CRASESVDNYGISFMNWFQQKPGQPPKLLIFAAS
NQGSGVPARFSGSGS GTDFSLNIHPMEEDDTAMYFCHQSKEVPWTFGGGTKLEI
K (SEQ ID NO:18)
2-K2-A DILMTQ SP S SMSVSLGDTVS ITCHASQGIS SNIGWLQQKPGKSFKGLIYHGTNLED
GVP SRFSGSGSGADY SLTIS SLESEDFADYYCVQYAQFPFTFGSGTKLEIK (SEQ
ID NO:20)
6-H6-A DIVLTQSPASSAVSLGQRATFSCRASQSVSTSSYSFMHWYQQKPGQPPKLLIKYA
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
SNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPPTFGGGTNLEIK
(SEQ ID NO:22)
1-Al 9-A DIVL TQ SPA SLAVSL GQRATI S CKA S Q SVDYDGDSYMNWYQQKPGQPPKLLIYA
ASNLES GIP ARF S GS GSGTDFTLNIHPVEEEDAATYYCQQ SNEDPFTFGS GTKLEI
K (SEQ ID NO:24)
10-015-A D IVL TQ SPA SL AVSL GQRATI S CRA SK S VS A S GY SYMHWYQQKP
GQPPKLLIYLA
SNLESGVPARFSGSGSGTDFTLNVHPVEEEDAATYYCQHSRELPFTFGSGTKLEI
K (SEQ ID NO:26)
6-113-A DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYMHWYQQKPGQPPKLLIYLA
SNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPYTFGGGTKLEI
K (SEQ ID NO:28)
5-K4-A DIVLTQSPASLAVSLGQRATIS CRASESVEYYGTSLMQWYQQKPGQPPKLLIYAA
SNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKVPWTFGGGTKLEI
K (SEQ ID NO:30)
12-G18-A DIVLTQSPASLAVSLGQRATIS CRA SE S VDNYGI SFMNWFQQKP GQPPKLLIYAE S
NQGSGVPARFSGSGS GTDFSLNIHPMEEDDTAMYFCQQSKEVPYTFGGGTKLEI
K (SEQ ID NO:32)
10-M2 1-A DIQMTQ SP S SL S A SL GGKVTIT CKA S QDINRYIAWYQHKPGK GPRLL IHYT S
TLQP
GIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLLFTFGSGTKLEIK (SEQ ID
NO:34)
12-M1 1-A QIVLTQSPAIMSASPGEKVTMTCSASSSISYMHWYQQKPGTSPKRWIYDTSKLAS
GVPTRFNGSGSGTSYSLTISSMEAEDAATYYCHQRSSYRTFGGGTKLEIK (SEQ
ID NO:36)
5-C11-A D IVMSQ SP S SL AVS AGEKVTMS CKS SQSLLNSRTRKNYLAWYQQKPGQSPKLLI
YWASTRES GVPDRFTGS GS GTD FTL TIS SVQADDLAVYYCKQ SYNLLTFGAGTK
LELK (SEQ ID NO:38)
16-J5-A DIVLTQSPASLAVSLGQRATISCKASQ SVDYDGDSYMNWYQQKPGQPPKLLIYA
ASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPPTFGGGTKLEI
K (SEQ ID NO:40)
7-N2-A DIVMSQ SP S SL AVS AGEKVTMS CK S SQSLLNSRTRKNYLAWYQQKPGQSPKLLI
YWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNHMYTFGGGT
KLEIK (SEQ ID NO:42)
VL: light chain variable region
Table 3: CDR Regions 1-3 of heavy chain for anti-TIM-3 mAbs
mAb HC
clones CDR1 (SEQ ID NO:) CDR2 (SEQ ID NO:) CDR3 (SEQ ID NO:)
20-L10-A GYTFTNYG (43) INTYTGEP (44) ARDAMDY (45)
15-L23-A GYTFTNYG (46) INTYTGEP (47) ARDTMDY (48)
8-F3-A GYTFTNYG (49) INTYTGEP (50) ARDLEDY (51)
7-P15-A GYTFTNYG (52) INTYTGEP (53) ARDLMDY (54)
18-N1-A GYTFTSYW (55) INPSNGGT (56) ARSYYTYDAIDY (57)
18-022-A GYTFTSYV (58) INPYNDVT (59) ARS SDYDD GHWYFD V (60)
16-L3-A GYTFTSYY (61) IYPGDGST (62) ATDRYDVAY (63)
16-K5-A GYTFTSSD (64) IFPGDGST (65) ARGLDY (66)
19-A14-A GYSITSDYA (67) ISYSGST (68) ARDGRYDYYAMDY (69)
2-K2-A GYTFTTYW (70) INPSTGYT (71) ANDHEGGFAY (72)
6-H6-A GYTFTDYN (73) IDPNYDST (74) ARGGHYRYDGYYAMDY (75)
1-A19-A GYTFTDYN (76) IDPNYDIT (77) ARGGHYRYDGYYALDY (78)
10-015-A GYTFTDYE (79) IHPGSGGT (80) SRSYYRYTGYFDV (81)
6-113-A GYSFTGYN (82) IDPYYGVT (83) ASYSLTYDGYYPFAY (84)
5-K4-A GYSFTAYY (85) ISCFNGAT (86) ARRGDFDRPEFAY (87)
51
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
12-G18-A GYSITSDYA (88) ISYSGST (89) ASNYRYDYWFFGV (90)
10-M21-A GDSITSGY (91) ISYSGST (92) VSGNHFDY (93)
12-M11-A GYFTSYW (94) INPITGYT (95) ARGVENFDYLYAMDY
(96)
5-C11-A GFTFSDFY (97) ISDGGSYT (98) ASGYYYGSDYVMDY (99)
1645-A GFTFSSFG (100) ISSGSSTI (101) ARWGRWADFDY (102)
7-N2-A GFSLTGFG (103) IWGDGST (104) ARDYYGYVGNAMDY (105)
HC: heavy chain; CDR: complementarity determining region
The HC CDRs for the anti-TIM-3 mAbs were determined utilizing the IMGT method
(Lefranc, M.-P. et al., Nucleic Acids Res. 1999; 27:209-212).
Table 4: CDR regions 1-3 of the light chain for anti-TIM-3 mAbs
LC
mAb clones
CDR1 (SEQ ID NO:) CDR2 (SEQ ID NO:) CDR3 (SEQ ID NO:)
20-L10-A QSLVHSNGNTY (106) KVS (107) SQNTHVPWT (108)
15-L23-A QSLVHSNGNTY (109) KVS (110) SQNTHVPWT (111)
8-F3-A QSLVHSNGNTY (112) KVS (113) SQTTHVPWT (114)
7-P15-A QSLVHSNGNTY (115) KVS (116) SQSIHVPYT (117)
18-N1-A QSLLNSRTRKNY (118) WAS (119)
KQSYNLYT (120)
18-022-A QSVDYDGESY (121) VAS (122) QQSNEDPTWT (123)
16-L3-A SSISSSN (124) GTS (125) QQWSSYPLT (126)
16-K5-A QDINSY (127) RAD (128) LQYDEFPLT (129)
19-A14-A ESVDNYGISF (130) AAS (131) HQSKEVPWT (132)
2-K2-A QGISSN (133) HGT (134) VQYAQFPFT (135)
6-H6-A QSVSTSSYSF (136) YAS (137) QHSWEIPPT (138)
1-A19-A QSVDYDGDSY (139) AAS (140) QQSNEDPFT (141)
10-015-A KSVSASGYSY (142) LAS (143) QHSRELPFT (144)
6-I13-A KSVSTSGYSY (145) LAS (146) QHSRELPYT (147)
5-K4-A ESVEYYGTSL (148) AAS (149) QQSRKVPWT (150)
12-G18-A ESVDNYGISF (151) AES (152) QQSKEVPYT (153)
10-M21-A QDINRY (154) YTS (155) LQYDNLLFT (156)
12-M11-A SSISY (157) DTS (158) HQRSSYRT (159)
5-C11-A QSLLNSRTRKNY (160) WAS (161)
KQSYNLLT (162)
16-J5-A QSVDYDGDSY (163) AAS (164) QQSNEDPPT (165)
7-N2-A QSLLNSRTRKNY (166) WAS (167)
KQSYNHMYT (168)
LC: light chain; CDR: complementarity determining region
The LC CDRs for the anti-TIM-3 mAbs were determined utilizing the IMGT method
(Lefranc, M.-P. et al., Nucleic Acids Res. 1999; 27:209-212).
[00173] Example 2: TIM-3 and PtdSer binding assay using ELISA
[00174] To determine the effect of anti-TIM-3 antibodies on the interaction of
TIM-3
with phosphatidylserine (PtdSer), 384-well ELISA plates were coated with
PtdSer or
phosphatidylcholine (PtdChol) at room temperature. The wells were washed using
PBS
supplemented with 0.1% Tween-20 and then blocked using PBS supplemented with
2%
52
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
bovine serum albumin (BSA). Plates were washed and then incubated with a pre-
equilibrated mixture of purified antibodies (0, 0.03, 0.08, 0.25, 0.74, 2.22,
6.67, or 20
g/mL mAb) and TIM3(ECD)-huFc, a fusion protein containing the extracellular
domain
(ECD) of human TIM-3 and human Fc (huFc), in blocking buffer supplemented with
CaCl2. The plates were washed and then incubated with HRP-coupled anti-huFc
secondary antibody. Plates were washed, incubated with an HRP substrate, and
read
using a POLARstar Omega Microplate (BMG LABTECH). The assay was performed in
triplicate. The signal of TIM-3 binding to PtdSer was defined as 100% signal
and the
signal of TIM-3 binding to PtChol as zero (background) to set the assay
window. Results
of the inhibition of human TIM-3 binding to PtdSer by anti-TIM-3 monoclonal
antibodies
(mAbs) as demonstrated by the ELISA assays are shown in FIGS. 1A-1F.
[00175] Example 3: FACS binding analysis of purified antibodies
[00176] A human TIM-3-expressing plasmid was made and transiently transfected
into
HEK293T cells. After approximately 48 hours, cells were transferred to a 384-
well V-
bottom plate. Cells were washed with ice-cold FACS buffer (PBS supplemented
with 1%
BSA) and incubated with purified mAbs with gentle agitation at 4 C for 45
minutes. The
cells were washed with FACS buffer and incubated with an anti-mouse secondary
Ab
AlexaFluor488. The cells were washed and analyzed by FACS. Results of the FACS
binding analysis of the anti-TIM-3 mAbs are provided in FIG. 2.
[00177] Example 4: Dissociation constant (KD) analysis
[00178] Binding experiments were performed on OCTET Red96 at 25 C. Antibodies
were loaded onto Anti-Mouse Fc (AMC) biosensors. Loaded sensors were dipped
into
serial dilutions of antigen. Kinetic constants were calculated using a
monovalent (1:1)
model. The assay buffer was PBS supplemented with 0.1% BSA, 500 mM NaCl, 0.02%
Tween-20, pH 7.2. The dissociation constant for antibody-antigen binding was
determined for the anti-TIM-3 monoclonal antibodies and is shown below in
Table 5.
53
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
Table 5: KD values for anti-TIM-3 mAbs
KB (nM) KB (nM)
mAb clones
Human TIM-3 Cyno TIM-3
5-K4-A 1.8 6.7
16-J5-A 2.7 0.054
10-015-A 3.1 2.9
18-N1-A 1.1 14
16-K5-A 7.9 6.4
6-I13-A 9.9 5.2
10-M21-A 16 7.5
16-L3-A 14 6.5
1-A19-A 2.2 2.8
15-L23-A 13 8.9
20-L10-A 10 4.1
8-F3-A 1.6 22
[00179] Example 5: Humanization of anti-TIM-3 mAb
[00180] The mouse anti-TIM-3 mAb 16-K5-A was humanized to reduce the potential
of immunogenicity when used in human patients. The sequences of the variable
regions
of the heavy and light chains (VH and VL) were compared with the human
antibody
sequences in the Protein Data Bank (PDB) database and homology models were
built by
applying SWISS-modeling. The CDRs in both the heavy and light chains of the
mouse
mAbs were grafted into human frameworks that have the highest possibility of
maintaining the proper structure likely required for antigen binding.
Backmutations from
human residues to mouse residue were designed when necessary. The sequences of
the
humanized VH and VL regions are shown in Table 6. The humanized VH and VL
regions were fused to the constant regions of human IgG4 heavy chain and kappa
light
chain, respectively. Constructs corresponding to the mAb sequences were used
for
transient transfection in 293E cells The resulting antibody was purified by
Protein A
affinity column.
54
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
Table 6: Sequences of heavy chain and light chain variable regions of
humanized anti-
TIM-3 mAbs
SEQ
VH/VL SEQUENCE ID
NO:
EVQLVESGGGLVQPGGSLRLSCAASGYTFTS SDINWVRQAPGKGLVWIGW
H1 IFPGDGSTKYTP SLKDQATLSTDKAKNTAYLQMNSLRAEDTAVYFCARGL 171
DYWGQGTLVTVS S
EVQLVESGGGLVQPGGSLRLSCAASGYTFTS SDINWVRQAPGKGLVWIGW
H2 IFPGDGSTKYTP SLKDQATL STDLAKNTAYLQMNSLRAEDTAVYFCARGL 172
DYWGQGTLVTVS S
QVQLQESGPGLVKPSETL SLTCTAS GYTFTS SDINWVRQPPGKGLEWIGWI
H5 FPGDGSTKYNPSLKSRATL STDKSKNQASLNLD SVSAADTAIYFCARGLDY 173
WGKGSTVTVS S
QVQLQESGPGLVKPSETL SLTCKASGYTFTS SDINWVRQPPGKGLEWIGWI
H7 FPGDGSTKYNPSLKSRATL STDKSKNQASLNLS SVTAADTAVYFCARGLD 174
YWGKGTTVTVSS
DIQMTQ SP S SLSASVGDRVTITCKASQDINSYLGWFQQKPGKAPKTLIYRA
Li DRLVDGVPSRFS GS GS GQDYTFTIS SLQPEDIATYYCLQYDEFPLTFGQGTK 175
LEIK
DIQMTQ SP S SLSASVGDRVTITCKASQDINSYLGWFQQKPGKAPKTLIYRA
L5 DRLVDGVPSRFS GS GS GQDYTFTIS SLQPEDIATYYCLQYDEFPLTFGPGTK 176
VDIK
H1, H2, H5 and H7 are humanized VH sequences; Li and L5 are humanized VL
sequences. H1L1, H2L1, H5L5 and H7L5 refer to the humanized mAbs constructed
using a specific VH (e.g., H1) and a specific VL (e.g., L1) combination (to
produce
H1L1).
[00181] Example 6: ELISA binding analysis for chimeric and humanized anti-
TIM-3 mAbs
[00182] Recombinant human TIM-3(ECD)-6His in carbonate coating buffer was
coated on an ELISA plate at 4 C overnight. The chimeric and humanized versions
of
anti-TIM-3 mAbs (H1L1, H2L1, H5L5 and H7L5) were added to the plate at
different
concentrations after being washed and incubated for 1 hour at room
temperature. The
plate was washed and antibody-binding was detected by adding anti-human IgG
conjugated to horseradish peroxidase (hIgG-HRP) (ThermoFisher Scientific,
Cat#: 31410)
and incubating for 60 minutes. After washing, the ELISA was developed using
One-step
Detection Solution (ThermoFisher Scientific, Cat #: 34028), which was measured
as the
absorbance at 450 nm. Results are shown in FIGS. 3A and 3B.
CA 03070295 2020-01-16
WO 2019/023410
PCT/US2018/043800
[00183] It will be appreciated by those skilled in the art that changes could
be made to
the embodiments described above without departing from the broad inventive
concept
thereof. It is understood, therefore, that this invention is not limited to
the particular
embodiments disclosed, but it is intended to cover modifications within the
spirit and
scope of the present invention as defined by the present description.
56
